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 Cat-1/Git-1 is a multi-functional protein that acts as a GAP (GTPase-activating 
protein) for Arf GTPases, as well as serves as a scaffold for a number of different 
signaling proteins. Cat-1 is best known for its role in regulating cell shape and promoting 
cell migration. However, whether Cat-1 might also contribute to cellular transformation 
is currently unknown.  Here we show that ~95% of cervical tumor samples examined 
over-express Cat-1, suggesting that the up-regulation of Cat-1 expression is a frequent 
occurrence in this type of cancer. We further demonstrate that knocking-down Cat-1 from 
NIH3T3 fibroblasts expressing an activated form of Cdc42 (Cdc42 F28L), or from the 
human cervical carcinoma (HeLa) cell line, inhibits the ability of these cells to form 
colonies in soft agar, an in vitro measure of tumorgenicity. The requirement for Cat-1 in 
the anchorage-independent growth of HeLa cells is dependent on its ability to bind 
paxillin, while its Arf-GAP activity had a negative effect. Collectively, these results 
suggested that Cat may be acting as an effector for activated Arf GTPases in promoting 
cellular transformation, and the binding of Cat to paxillin is a critical step in mediating 
the effector function. In support of this idea, the co-expression of Cat-1 and an activated 
form of Arf6 in fibroblasts was sufficient to induce transformation in normal NIH3T3 
fibroblasts. These findings highlight novel roles for Cat-1 and its interactions with the Arf 
GTPases and paxillin in oncogenic transformation. 
! We then go on to show that paxillin, and Hic-5, a close homolog of paxillin that also 
binds to Cat, act to negatively regulate the anchorage-independent growth of HeLa 
cervical carcinoma cell line as read-out by soft agar assay. Also, we show that binding of 
Cat to paxillin, but not Hic-5, is the critical function of Cat that is important for mediating 
the role of Cat in promoting anchorage-independent growth. These findings suggested 
that Cat promotes cellular transformation by binding to paxillin to block paxillin from 
negatively regulating cellular transformation. 
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Chapter 1 
 
Introduction 
 
Normal cells require tight regulation over mitogenic signaling to achieve the 
appropriate growth and proliferation of cells. Insufficient signaling in this context 
prevents cells from achieving the appropriate rate of cell growth. However, excessive 
mitogenic signaling can potentially result in a cancerous growth. Thus, signaling needs to 
be tightly controlled and it is critical to understand the mechanisms underlying this 
regulation in order to fully appreciate how disease states progress (i.e., cancer) and to 
suggest novel points of intervention for cancer therapies. The purpose of this thesis is to 
determine the role of Cool Associated Tyrosine phosphorylated - 1 (Cat-1) / G protein-
coupled receptor kinase interacting ArfGAP- 1 (Git-1) in promoting the aberrant growth 
of transformed cells and human cancer cells, as well as to gain insight into the molecular 
mechanisms through which Cat-1 mediates its effects. 
 
Initiation of Signal Transductions 
It is well established that normal cells require the regulation of mitogenic growth 
signals in order to proliferate (1). Among the best-known examples of such signals are 
diffusible growth factors, which initiate their effects when they bind to their 
corresponding transmembrane receptors that reside on the plasma membranes of the 
receiving cells. Nearly all cell types express several different types of receptors, poising 
them to respond to a variety of cues that a cell may receive from its surroundings. One of 
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the best studied group of receptors is the superfamily of receptor tyrosine kinases that 
include the epidermal growth factor (EGF) receptor, the insulin-like (IL) growth factor 
receptor, and the platelet-derived growth factor (PDGF) receptor.  
 
One of the earliest identified and best-characterized growth hormones is the 
epidermal growth factor (EGF). When Rita Levi-Montalcini observed that the 
transplantation of mouse tumors into chick embryos spurred the growth of nerve cells 
near the tumor and induced their differentiation, it was realized that there must be some 
factor coming from the tumor cells that elicited this biological response from the chick 
nerve cells (2). Using newborn mice as a model system to follow-up these observations 
and identify the factors that were prompting cell growth and precocious differentiation, 
Stanley Cohen purified the polypeptide that was responsible for this biological activity, 
which was later named Epidermal Growth Factor (EGF) (3). He also participated in the 
purification of the factor that was responsible for Rita Levi’s observation, which was 
named Nerve Growth Factor (NGF). Since their early findings, numerous studies have 
shown that the signaling events initiated by EGF are intimately linked to normal cell 
growth and proliferation. Moreover, de-regulation of EGF-mediated signaling events, 
either by overproduction of EGF or by over-expression of the EGF receptor (EGFR), has 
been linked to the development of human cancer, including those derived from the brain, 
lung, colon, and breast (4).  
 
The initial binding of EGF to the EGFR, and the subsequent series of conformational 
changes that the EGFR undergoes to become activated is a good example of the high 
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degree of regulation to which mitogenic signaling pathways are subjected. The EGFR 
contains an extracullular domain which is connected to the cytoplasmic tyrosine kinase 
domain by a single transmembrane region (5) (Figure 1.1). EGF receptor signaling is 
initiated when EGF binds to the extracellular domain of the receptor, which is composed 
of the EGF-binding domains and dimerization motifs (6,7). The binding of EGF to the 
EGF-binding domains on the receptor induces the exposure of the dimerization motifs, 
allowing monomeric EGFRs to come together to form dimers. Juxtapositioning of the 
cytoplasmic domains of the EGFRs via the dimerization of their extracellular domains is 
thought to induce the receptor’s kinase activity. Interestingly, the kinase domains of the 
EGFR come together in an asymmetric fashion (8),(9) (Figure 1.2). The kinase domain is 
composed of two lobes, an N-terminal lobe and a C-terminal lobe, and the asymmetric 
positioning of the C-terminal lobe of one EGFR monomer with the N-terminal lobe of the 
other EGFR monomer enables the C-terminal lobe to act like a cyclin in the cyclin/Cdk 
complex, and pull the activation loop away from the active site of the N-terminal lobe on 
the neighboring receptor, rendering the active site accesible for the binding of ATP. This 
results in the transphosphorylation of several tyrosine residues found within the C-
terminal tails of the adjoining monomers making up the EGFR dimer. 
 
Through EGF-induced dimerization and trans-autophosphorylation of the EGFR, the 
receptor is now able to activate a myriad of signaling pathways. It does so by recruiting 
signaling proteins that contain Src Homology 2 (SH2) or Phophotyrosine Binding (PTB) 
domains to specific tyrosine residues that are phosphorylated on the EGFR. A classical 
example of this involves Grb2, a SH2-domain containing protein that engages the  
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phosphorylated EGFR, resulting in the activation of the Ras-Erk mitogenic pathway in 
cells. In addition to activating the Ras-Erk signaling cascade, the EGFR is also able to 
induce the activation of several other signaling proteins that work together in a 
coordinated fashion to regulate cell cycle progression, as well as cause changes in the 
expression pattern of specific genes. These signaling events downstream of the receptor 
must be tightly regulated in order to maintain a normal growth rate in cells. An important 
feature of this regulation is the role played by members of the Ras superfamily of 
GTPases. These proteins undergo a GTP-binding/GTP hydrolysis cycle that allows them 
to act as molecular switches. When in the GTP-bound state, they engage and activate 
their signaling partners (“effectors”), whereas GTP hydrolysis serves to switch off the 
GTPase as thereby terminate its downstream signals. 
 
Ras superfamily of GTPases 
There are over 60 members of the Ras superfamily of GTPases. They are commonly 
divided into five subfamilies; Ras, Rho, Rab, Arf, and Ran (Figure 1.3), based on the 
sequence homologies. These proteins have similar molecular weights that typically range 
from 21 kDa to 25 kDa, and they are all capable of binding and hydrolyzing GTP, 
although their intrinsic GTP hydrolytic activity is typically low. Importantly, the 
activation of these proteins is dependent on whether they are bound to GTP or GDP, 
hence their classification as ‘molecular switches’ (Figure 1.4). Despite the high degree of 
sequence homology that exists between the members of the Ras superfamily, each 
member has been shown to have distinct functions within the cell. For example, a well-
characterized and specific role for the Rho subfamily which includes Cdc42, Rac, and  
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Rab families have been implicated in the trafficking of intracellular vesicles. A diagram 
highlighting the members of the Ras superfamily and some of the roles that they play in 
cells is shown in Figure 1.3.  
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Rho is their ability to impact cell morphology. On the other hand, the Arf and Rab 
families have been implicated in the trafficking of intracellular vesicles. A diagram 
highlighting the members of the Ras superfamily and some of the roles that they play in 
cells is shown in Figure 1.3. 
 
Ras was the first protein to be identified in the Ras superfamily and it is best known 
for its effects on cell growth. It was identified in 1979 as a transforming element of the 
Harvey and Kristen rat sarcoma virus by Edward Scolnick (10). In 1982, Geoffrey M. 
Cooper at Harvard (11), Mariano Barbacid and Stuart A. Aaronson at the NIH (12), and 
Robert Weinberg at MIT (13) identified Ras as the first human oncogene, and is now 
known to be mutated in at least 30% of all human cancers (14). Like all small GTPases, 
Ras sends signals when it is in the GTP-bound state. Importantly, many of the mutations 
that occur in Ras cause it to remain in the active, GTP-bound state, for an extended 
period of time resulting in an enhanced activation of its effectors. The importance of 
these mutations in promoting human cancer will be discussed in more detail below. 
 
Regulating the activities of small GTPases 
The activation of small GTPases is mediated by a group of proteins referred to as 
guanine nucleotide exchange factors (GEFs) (Figure 1.4). GEFs activate the small 
GTPases by facilitating the exchange of the bound GDP for GTP, and this occurs in 
response to signals such as those triggered by EGF. Specifically, the Ras protein is 
activated by a GEF called Son of Sevenless (SOS) (15,16), which is recruited to the EGF 
receptor when it is auto-phosphorylated on a specific tyrosine residue. The adaptor 
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protein Grb2 mediates the recruitment of SOS to the EGFR(17). The SH2 domain of 
Grb2 recognizes a specific phosphorylated tyrosine residue of Y-1068 on the EGFR (Tyr 
1068) while the SH3 domains of Grb2 bind to SOS (18). Once recruited to the receptor, 
SOS is brought into close proximity to Ras which resides on the plasma membrane.  
 
Although each GEF responds to specific signals that enable it to engage and activate 
its substrate GTPase, the basic mechanism underlying the ability of a GEF to stimulate 
GDP-GTP exchange is conserved. Specifically, GEFs induce at least two types of 
conformational changes in their target small GTPases that catalyze the dissociation of 
GDP and enable the loading of GTP. In the case of SOS, the first change induced in Ras 
causes the displacement of the switch 1 region, resulting in an ‘opening-up’ of the 
nucleotide-binding site. The second conformational change in Ras caused by SOS is a 
distortion of the switch 2 region that disrupts the essential interactions that occur between 
the phosphate group of the bound nucleotide and the coordinating Mg2+, a key cofactor 
critical for high affinity binding of GDP. As a result, the affinity of the GTPase (in this 
case Ras) for the GDP is substantially weakened causing its dissociation from Ras. 
Because the concentration of GTP is 10-fold higher than GDP in cells, it is more likely to 
bind to the GTPase. The binding of GTP to Ras will then displace the GEF from the 
GTPase. The GTP-bound, or active form of the small GTPase is then able to carry-out 
specific functions in cells by engaging effectors.  
 
As important as inducing the signaling capabilities of small GTPases at the right time 
and place, ensuring that they are only active for a finite time is also essential. However, 
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the small GTPases themselves have typically low intrinsic GTP hydrolytic activity, 
making it necessary for another protein to stimulate this reaction. This is achieved by a 
class of proteins called GTPase Activating Proteins or GAPs (Figure 1.4). Thus, GAPs 
play a critical role in the termination of signaling by the GTPases. GTP hydrolysis 
involves the nucleophilic attack of a water molecule on the !-phosphate of GTP, 
requiring the proper orientation and polarization of the water molecule on the opposite 
site of the leaving group (i.e., GDP). GAP proteins function by stabilizing the transition 
state the GTP hydrolytic reaction. Typically, GAPs introduce a conserved arginine 
residue, known as ‘the argnine finger’, into the active site to stabilize the position of 
catalytic Gln (e.g., Q61 on Ras), and to neutralize the negative charges developing on the 
phosphates during the transition state for GTP hydrolysis.   
 
The mechanism underlying how Ras, the first human oncogene identified, promotes 
cancer progression, underscores the importance of regulating the GTP binding/GTP 
hydrolysis cycle of small GTPases. Ras is frequently found to be mutated in human 
cancer. One of the most common spontaneously occurring mutations in Ras occurs at 
position 12 where a valine substitutes for a glycine residue. This mutation results in a Ras 
protein that has little GTP-hydrolytic activity (19,20). Thus, this mutant form of Ras is 
persistently active, resulting in the sustained activation of many mitogenic pathways, 
including the Ras-Raf-Mek-Erk pathway.  
 
Cdc42 is a member of the Rho subfamily of the Ras superfamily of small GTPases 
(Figure 1.3). Like Ras, Cdc42 impacts mitogenic signaling, and its deregulation can also 
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lead to cellular transformation. Initially identified in a screen as an essential gene 
necessary for cell division in yeast, the Cerione laboratory cloned the human version of 
this protein in 1990 while searching for novel signaling partners of the EGF receptor (21). 
The role of Cdc42 in mammalian cell growth and cellular transformation was initially 
highlighted in a study that identified the product of the Dbl (for Diffuse B-cell 
lymphoma) as a GEF for Cdc42 (22). Dbl is the founding member of a family of 
oncogenic proteins which all function as GEFs for members of the Rho family of 
GTPases. Notably, these proteins commonly contain a tandem Dbl homology domain 
(DH domain) and Pleckstrin homology domain (PH domain), with the DH domain being 
responsible for the catalytic activity, and the PH domain mediating the appropriate 
cellular localization via its ability to interact with specific phospholipids (23). The fact 
that the ability of Dbl, when expressed in NIH3T3 fibroblasts, to induce cellular 
transformation was dependent on its GEF activity, suggested that Cdc42 may be involved 
in promoting malignant transformation.  
 
Dominant-active mutant forms of Cdc42 have been discovered and examined for their 
ability to induce or promote transformation. The GTP hydrolysis-defective mutants, 
including the Cdc42 (G12V) or Cdc42 (Q61L) mutants, in certain cellular contexts, were 
capable of inducing transformation, but more often they were toxic to cells. Subsequently, 
a Cdc42 mutant (F28L) capable of spontaneously exchanging GDP for GTP while still 
being able to hydrolyze GTP (thus called a “fast-cycling” mutant) was generated and 
demonstrated to be strongly transforming when stably expressed in NIH3T3 fibroblasts 
(24). Thus, it seems that, similar to Ras, enhancing Cdc42’s signaling capabilities is 
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sufficient to drive transformation. However, distinct from Ras, Cdc42 needs to rapidly 
cycle between its GDP-bound and GTP-bound states in order to do so.  
 
The mechanism underlying the ability of Cdc42 to induce cellular transformation also 
turns out to be different from how Ras drives transformation in that, unlike Ras, which 
transforms by activating its downstream effectors, Cdc42 prolongs the activation of the 
EGFR (25). Activated Cdc42 is able to form a complex with the E3-ubiquitin ligase Cbl, 
sequestering it from its substrate, the EGFR. This extends the half-life of the EGFR, 
sending mitogenic signals that drive cellular transformation. Consistent with this idea, 
inhibiting the EGFR using the EGFR kinase-inhibitor AG1478, is sufficient to block 
Cdc42-mediated cellular transformation, whereas cells transformed by oncogenic Ras are 
completely insensitive to this treatment.  
 
As can be appreciated from the examples described above, the appropriate regulation 
of cell signaling events by the small GTPases has important consequences for normal 
cellular functions, and when de-regulated, in promoting disease states such as cancer. The 
Cerione group has long been interested in understanding how the activities of small 
GTPases are regulated. To this end, the laboratory discovered a protein called Cat as a 
potential mediator of mitogenic signaling. My thesis project is focused on understanding 
the role of Cat in cellular transformation. Cat is a GAP for the ADP-ribosylation factor 
(Arf) family of small GTPases, and a scaffold protein that can interact with a variety of 
signaling molecules. I will first provide some background information on ArfGTPases 
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and ArfGAPs, and then I will focus on the known cellular functions of Cat in a later 
section.  
 
Arf GTPases  
Arf, originally identified as a cofactor required for the cholera toxin-catalyzed ADP-
ribosylation of the ! subunit of the heterotrimeric G protein Gs, is a member of a Ras 
superfamily that has been primarily implicated in membrane trafficking and regulating 
organelle structure (Figure 1.3). In mammals, the Arf family is subdivided into three 
classes based on their primary amino acid sequence similarities; Arf1, Arf2, and Arf3 
comprise Class I, Arf4 and Arf5 comprise Class II, and Arf6 is the sole member of Class 
III (26,27). At least one member in each of these classes is conserved in all metazoans, 
whereas yeast lack only the Class II members of the Arf GTPases. Like other small 
GTPases, Arf GTPases bind to guanine nucleotides, and their activity is regulated by the 
GTP-binding / GTP-hydrolysis cycle. The binding of GTP by Arfs and its subsequent 
hydrolysis are regulated by a family of GEFs and GAPs. The GEFs commonly contain 
Sec7 domains, which correspond functionally to the DH domain found in the Dbl family 
of Rho GEFs. The Sec7 domain stimulates GDP release from the Arfs, allowing GTP to 
then bind to the protein. Arf GAPs catalyze the hydrolysis of GTP to GDP in Arf 
GTPases, which is critical because Arf GTPases exhibit no detectable intrinsic GTP 
hydrolysis activity (28). Arf GAPs have a conserved zinc-finger catalytic domain that 
contains the conserved arginine finger that is also found in Rho GAPs. Like other Ras 
superfamily members, Arf GTPases are post-translationally modified with lipids to help 
them bind to specific membrane compartments. However, Arf GTPases are uniquely 
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myristolated at their N-terminus as opposed to being geranylgeranylated or farnesylated 
at the C-terminus like most other small GTPases (29). 
 
Arf GAPs 
Arf GAPs are a family of proteins that are ubiquitously expressed in eukaryotes and 
regulate the activation of Arf GTPases. Members of the family share a conserved 
functional domain, which includes a signature zinc-binding motif (CX2CX16CX2CX4R) 
that has a structural, rather than a catalytic role (30). There are at least 32 genes in 
humans that encode proteins with Arf GAP domains and they can be categorized into two 
types according to their protein structure (Figure 1.5); Arf GAP1 type and AZAP type. 
The major distinguishing feature of these two groups has to do with the location of the 
Arf GAP domain. Members of the Arf GAP1 group have their Arf GAP domain located 
at the N-terminus of the protein, while the AZAP type of GAPs has the Arf GAP domain 
between the PH and ankyrin repeat domains (31). Arf GAP1-type proteins include 
ArfGAP1, SMAP, and Cat. The AZAP-type group includes ASAP, ARAP, ACAP and 
AGAP. A majority of the Arf GAPs are multidomain-containing proteins with molecular 
weights that range from 80 kDa to 200 kDa. 
 
Because Arf GTPases have undetectable intrinsic rates of intrinsic GTP hydrolysis, the 
manifestation of this activity relies solely on the binding of an ArfGAP. However, as the 
complex domain structure of the Arf GAP proteins might suggest, their cellular roles 
often involve additional functions through their ability to bind to several other signaling  
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proteins. In support of this idea, there are many instances where the abilities of the Arf 
GAPs to associate with their binding partners are unrelated to their GAP function (31) 
 
In fact, Arf GAPs are able to interact with numerous proteins that include vesicle 
cargo/coat/adaptor proteins, lipid-modifying enzymes, and protein kinases. Evidence is 
accumulating that Arf GAPs function as more than just terminators of Arf GTPase 
activity but also as signaling effectors where they work as scaffolds, coordinating the 
interactions between multiple proteins to efficiently carry out the functions of the 
activated Arf GTPases (32). One of the best examples of this came from a study 
performed in yeast where Arf GAPs were identified in a screen for suppressors of loss of 
Arf GTPase function (33). If Arf GAPs were solely acting as terminators of Arf GTPase-
signaling, then over-expressing Arf GAPs in yeast would not have resulted in the rescue 
of the loss of Arf GTPase phenotype seen in this study. Thus, it is becoming clear that 
Arf GAPs can influence the functions of Arf GTPases on a number of levels. Indeed, the 
Arf GAP, Glo3, has been shown to facilitate the formation of an Arf1-mediated priming 
complex that is composed of an activated Arf GTPase, coatamer, and cargo molecules 
(34). Also in humans, two GAPs for Arf1, namely ArfGAP2 and ArfGAP3, interact with 
the COP I and SNARE proteins and participate as essential factors for vesicle formation, 
working as downstream effectors for Arf1 (35). In fact, a similar mode of regulation 
where GAPs act to both potentiate and terminate GTPase signaling, has been suggested 
for GPCR signaling where RGS proteins act as both signal amplifiers and signal 
terminators (36,37).  
 
! #$!
Identification of Cat 
Cat, also referred to as Git (for G-protein coupled receptor kinase interactor) or PKL 
(for paxillin kinase linker), is a multifunctional protein that is known to regulate the 
activity of certain members of the Arf family of small GTPases, as well as function as a 
scaffold that brings various proteins together via its numerous protein-binding domains 
(38). Cat is conserved from C.elegans to humans (39). All mammals studied thus far 
express two Cat homolog proteins; Cat-1 and Cat-2. The amino acid sequences of these 
homologs are 65% identical and 85% similar. The expression profiles of these proteins 
have been studied in mice, using a ‘gene-trap’ approach (40), where a reporter gene (i.e., 
beta-galactosidase) was inserted into an exon of an endogenous gene of interest, and 
when expressed results in the expression of a fusion protein consisting of parts of the 
endogenous protein and a reporter protein that can be readily detected. The expression of 
such a fusion protein, in turn, is under the regulation of the endogenous promoter for the 
gene of interest, thus allowing for a means to read out where a gene of interest is 
expressed in a model system (i.e., in a developing mouse embryo). In the Cat-gene-trap 
experiments carried-out in mice, Cat-1 was shown to be highly expressed in the brain, 
blood vessels, and mature spermatids, whereas Cat-2 was expressed more ubiquitously 
throughout the entire organism (40). Another distinction between Cat-1 and Cat-2 has to 
do with their alternative splicing. Unlike Cat-1, Cat-2 is alternatively spliced extensively 
resulting in more than 10 splice variants and 32 different transcripts (41). Except for 
‘Cat-2 short’, a splice variant that was identified in fibroblasts as a protein that co-
precipitated with paxillin, very little is known regarding the functions of these Cat-2 
isoforms (42). 
! #%!
 
Interestingly, the Cat-1 and Cat-2 proteins, that we often collectively refer to as Cat, 
were identified more than a decade ago through three independent lines of investigation 
as binding partners for three distinct proteins. In one such study performed by our 
laboratory, the Cat proteins were identified in pull-down assays as phosphorylated 
proteins that bound to Cool-1, a GEF for Cdc42 (38), whereas in the Lefkowitz 
laboratory these same proteins were named Gits (for G protein-coupled receptor kinase-
interacting protein), because they were discovered through their ability to bind to G-
protein coupled receptor kinase 2 (GRK2) (43). The Turner group then identified Cat-2 
(which they called PKL for Paxillin-Kinase-Linker) as a binding partner for paxillin, an 
important signaling molecule involved in cell migration (44). Protein sequencing 
performed on Cat-1 and Cat-2 showed that they contained an Arf GAP domain, and the 
Lefkowitz laboratory demonstrated that they could function as GAPs for the Arf GTPases 
(45). However, it is also worth emphasizing that the ability of the Cat proteins to interact 
with a variety of other proteins, (i.e., Cool, GRK, and paxillin) also highlights that they 
are multi-functional and participate in a number of cellular processes. For example, Cat-
Cool interactions possibly point to an interesting connection between a role for Cat in 
coordinating Arf GTPase activity with Cdc42 signaling, whereas the interactions between 
Cat and Grk, discovered in the Lefkowitz laboratory, suggest a role for the Cat proteins in 
receptor internalization. Moreover, the identification of Cat as a binding partner for 
paxillin was the first clue that Cat may also have a role in focal complex regulation.  
Indeed, since their discovery 10 years ago, the Cat proteins have been implicated in 
the regulation of various cellular processes such as neuronal dendritic spine formation 
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(46), neuronal synaptic activity (47), and T cell activation (48). However, the molecular 
mechanisms that have been proposed to explain their roles in mediating these diverse 
cellular functions have mostly centered around how Cat functions as a scaffold and 
affects cell morphology. For example, the localization of the Cool-Pak complex to focal 
adhesions through Cat-paxillin interactions was shown to be important for focal complex 
regulation and thus, cell morphology (49-51). However, there are reasons to suspect that 
Cat may have additional roles in cells. For instance, Cool-1, a major binding partner for 
Cat, has been shown to have a central role in Cdc42-mediated as well as Src-dependent 
cellular transformation (52,53). Moreover, Cat was shown to regulate the internalization 
of G-protein coupled receptors, as well as the internalization of EGFRs (54), raising the 
possibility that Cat may also impact mitogenic signaling.  
 
Domains and interacting partners of Cat 
Since its identification, there have been significant advances in our understanding of 
the structural domains in Cat that mediate its cellular functions. As depicted in Figure 1.6, 
Cat is a 95 kDa protein that contains multiple protein-interacting domains including an 
Arf GAP domain at the N-terminus, followed by a Spa2 Homology domain, a Coiled-coil 
domain, and a Paxillin binding sequence/Focal Adhesion Targeting homology at the C-
terminus. Each of the domains and the roles they play in Cat-mediated signaling events 
will now be covered below. 
 
 
 
! #G!
!"#$%&'()G'H/0' "+'/2'*%4'6*C'1%30&"2'/28'/'+,/443;8'0-/0'"20&%/,0+'I"0-'H33;J'/'
65!' 43%' H8,D<E>/,J' /28' 1/:";;"2J' /' 43,/;' ,3.1;&:' 1%30&"2' 0-/0' "+' "2?3;?&8' "2'
"20&#%"27+"#2/;"2#)' K5.! *-! 5+! D7;! 'DS!>*.0! *.-! D7;! 'DS! ,/45*+! 9/85.1,! 5.! .01! L2.174*+:-A! X.! *-! 5)91! ./! )*+,! ./! K//9=! 5! '&(! ;/7! K,8%#! 5+,! <58=! .07/:30! *.-! ]?5#!\/4/9/3H! N/45*+! C]\NFA! K5.! 59-/! )*+,-! ./! ?56*99*+=! 5+! *4?/7.5+.! ;/859! 8/4?916!?7/.1*+! .05.! 41,*5.1-! *+.137*+2,1?1+,1+.! -*3+59*+3! 5+,! *-! 59-/! *+I/9I1,! *+! 8199!4*375.*/+=!.07/:30!*.-!S56*99*+!^*+,*+3!]1Y:1+81!#!CS^]#F!,/45*+A!'
 
  
! #P!
 
  
!"
#$
!%
&
'(
)&
%*
'+
&
!,
-
&
.%
/0
&
!"
#&
12
34
5&
67
8
&
67
8
&
67
8
&
67
8
&
'(
9&
1*
)&
)(
&
%(
&
/5
&
6)
:&
1;
;<
45
&
=2
>?
<<?
@&
! #Q!
Arf GAP domain 
The Arf GAP domain lies within the N terminus of Cat. Arf GAP domains, in general, 
are unique compared to Rho GAPs in that they have a cysteine-rich, zinc-binding region 
with the binding of zinc having a role in promoting protein-folding rather than a direct 
catalytic function (30,31). Also, the molecular mechanism underlying Arf GAP-catalyzed 
GTP-hydrolysis was initially thought to be different from that used by Rho GAPs.  This 
was based on the crystal structure of the complex between Arf1 and ArfGAP1 (55), 
which showed that the catalytic arginine was remote from the active center of Arf1 
prompting the authors to propose a mechanism where coatamers provide the critical 
arginine and cooperate with ArfGAP1 to mediate catalysis. However, biochemical studies 
have consistently reported that the catalytic arginine of Arf GAPs is important for 
catalysis, and recent structural data of a complex between ASAP3, an Arf1 GAP, and its 
substrate Arf1 by Wittinghofer and colleagues confirmed that the invariable ‘arginine 
finger’ is indeed located at the active site (56). Currently, the general consensus in the 
field is that the arginine finger in an Arf GAP functions in a similar manner as in other 
Rho or Ras GAPs.  
 
The molecular mechanisms that regulate Cat’s Arf GAP activity are not well 
understood. In fact very little is known about the regulation of Arf GAP activities in 
general. There are a few proposed mechanisms for the regulation of Arf GAP1, the most 
well characterized of the Arf GAPs, but a consensus has proven to be difficult to be 
reached (57) . GTPase activation by Arf GAP1, for example, was proposed to be 
dependent on coatamers and inhibited by cargo. However, it has also been suggested that 
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ArfGAP1 senses the curvature of a vesicle, and GTPase activation by the GAP occurs 
only when the curvature exceeds a certain level. To date, there has been only one study, 
carried out by the Premont laboratory, that has investigated the regulation of Cat’s GAP 
activity (45). It focused on the relationship between the phosphorylation states of 
phosphatidylinositols (PIPs) and Cat’s GAP activity. This was because, at the time this 
study was performed, PIPs had been shown to regulate ArfGAP1 activity (58). The report 
shows that Cat’s GAP activity is stimulated by phosphatidylinositol 3,4, 5-trisphosphate 
(PIP3), but not by PIP2 or PIP, and was unique in that, unlike ArfGAP1 which works on 
Arf1 Arf2, Arf3 (class I Arfs), and Arf5 (a class II Arf), Cat was shown to work on all 
three classes of Arf GTPases including Arf6 (a class III Arf) in vitro. These findings, and 
the fact that Cat and Arf6 co-localize in cells, are the main reasons for the suggestions 
that Cats acts as a GAP for Arf6.  An interesting idea that stems from the study showing 
that the GAP activity of Cat is stimulated by PIP3, is that activated Arf6 is known to 
activate PIP5K to produce PIP2 (59), which, in turn, is the starting material to generate 
PIP3. Thus, a potential negative feedback loop may exist between activated Arf6 and the 
GTP hydrolysis activity of Cat.  
 
Ankyrin-Repeats domain 
Next to the GAP domain in Cat are the ankyrin-repeats. These are common motifs 
found in proteins that mediate numerous protein-protein interactions. Judging from the 
extensive interface that is formed by the Arf GAP domain and the ankyrin repeat domain 
in the crystal structure of PAPbeta2, another Arf1 GAP, the ankyrin repeat is thought to 
add structural integrity to the GAP domain (30). It should also be noted that the ankyrin 
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repeat of Cat was able to make an intramolecular interaction with the SHD domain within 
Cat, and disabling this intramolecular interaction using a mutant form of Cat resulted in 
enhanced intermolecular interactions with paxillin, as well as interactions mediated by 
the C-terminal PBS domain of Cat (60). Thus, the interactions between the ankyrin-
repeats and the SHD domain were auto-inhibiting the interactions between Cat and 
paxillin. Interestingly, auto-inhibitory interactions within ASAP1 also regulated its 
binding to Arf GTPases and its Arf GAP activity (61). It will be interesting to see 
whether a similar mechanism exists for Cat where its GAP activity is regulated by the 
same intramolecular interaction that regulated its interaction with paxillin.  
 
SHD domain 
C-terminal to the ankyrin-repeats in Cat is the Spa homology domain (SHD). Cat is 
the only mammalian protein known to contain this domain. In fact, the only other 
proteins identified that have SHD domains are the members of the Spa2 family of 
proteins in yeast (51). Interestingly, Spa2 proteins function in yeast by interacting with 
cell polarity proteins, and are essential for the polarized growth of yeast (62). The SHD 
domain in Cat is responsible for its ability to form a tight binding interaction with Cool-1, 
which is a GEF for the small GTPase Cdc42 (51). Thus, the Cat-Cool complex in cells 
brings together an activator of Cdc42 and a negative regulator of Arf6, providing a 
signaling node that coordinates the activities of the two small GTPases, Cdc42 and Arf6 
(61).  
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It has been recently suggested that the interaction between Cool and Cat is regulated 
by the phosphorylation – de-phosphorylation cycle of Cool (63). As will be discussed 
later, it was proposed that the phosphorylation of Cool by tyrosine kinases such as Src 
promote the dissociation of Cool and Cat. This model was used to explain why Src-
promoted migration was dependent on Cool.  
 
The SHD domain also mediates the interaction of Cat with Phospholipase C! (64). 
PLC" plays an important role in inositol signaling, as it catalyzes the production of Di-
Acyl Glycerol (DAG) and IP3 from phospholipids. IP3 then diffuses throughout the 
cytosol and binds to IP3 receptors expressed on the surfaces of the ER. Activation of the 
IP3 receptors, which function as Ca2+ channels, mediate the release of Ca2+ stores from 
the ER into the cytosol, which, in turn, initiates a myriad of signaling cascades that 
regulate many cellular activities including exocytosis and apoptosis. Cat’s ability to bind 
PLC" was reported to be important for promoting PLC!’s hydrolytic activity. Moreover, 
the phosphorylation state of PLC! is also known to activate its catalytic activity. 
Interestingly, one study showed that ectopically expressing a mutant form of Cat that was 
lacking its SHD domain (and therefore could not bind to PLC !) in cells, reduced the 
level of phosphorylated PLC! compared to WT Cat (64). This suggests that the binding 
of Cat to PLC! may help maintain it in a phosphorylated or active state. 
 
PBS2 domain 
Downstream of the SHD domain in the primary sequence of Cat-1, near its C-
terminus, is a paxillin-binding sequence 2 (PBS2) domain. Actually there are two 
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identified paxillin-binding sequences in Cat, and they are homologous to the paxillin-
binding regions found in other proteins such as the Focal Adhesion Kinase (Fak) (44). 
The first sequence, PBS1, is located immediately C-terminal to the ankyrin-repeats. PBS1 
has been reported to mediate paxillin interactions with Cat-2-short, an alternative splice 
variant of Cat-2 that is truncated at its C-terminal end. PBS2 of both Cat-1 and Cat-2 has 
been shown to bind to paxillin, and Small Angle X-ray Scattering (SAXS) experiments 
performed on the PBS2 domain of Cat suggest that it assumes a similar fold as the 
homologous sequence in Fak (65). Using this similarity, the Premont laboratory has been 
able to identify point mutations in this domain that specifically block the ability of Cat to 
interact with paxillin. Interestingly, the C-terminal end of Cat, where the PBS2 domain is 
located, has also been shown to be important for Cat to interact with many additional 
proteins including, Hic-5, huntingtin, liprin-alpha and eNOS (66),(67),(68).   
 
ArfGAP domain-interacting proteins : Arf1 and Arf6 
The Arf GAP domain of Cat has been shown to stimulate GTP hydrolysis in all three 
classes of Arf GTPases in vitro (45). However, cellular studies where Cat’s GAP activity 
was functionally disabled through mutation suggested Arf1 and Arf6 to be physiological 
substrates of Cat (42,69).  
 
Arf1 is best known for its role in regulating secretory membrane transport at the 
Golgi, where it mediates the trafficking between the Golgi and ER, as well as trafficking 
between Golgi cisternae. GTP-bound Arfs are bound to Golgi membranes and recruit 
coat protein complex I (COP I), clathrin AP (adapter proteins) coats, and GGAs (Golgi-
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associated !-adaptin ear homology domain Arf-interacting proteins) to budding transport 
vesicles (27). These coat proteins help sort cargo that will be carried into vesicles and 
trafficked between the ER and Golgi. While the role of Arf1 as being a critical mediator 
in recruiting coatamers to trafficking vesicles was initially identified through in-vitro 
biochemical studies, the in-vivo functions of Arf1 in vesicle-trafficking have been 
confirmed using the dominant-negative GTP binding-defective form of Arf1 (T27N) as 
well as the dominant-active, GTP-hydrolysis-defective mutant (Q71L). In particular, 
over-expressing Arf1 (T27N) resulted in the inhibition of vesicular export from the ER to 
Golgi, and the release of #-COP to the cytosol, whereas the expression of Arf1 (Q71L) 
resulted in the accumulation of vesicles in the Golgi, with #-COP remaining attached to 
Golgi membranes (70). Despite these extensive studies on the Arf1 GTPase and its role in 
Golgi trafficking, there are still outstanding questions that need to be answered regarding 
the exact mechanism of recruitment of Arf1 to the Golgi membrane, and the role of Arf1 
GTP-hydrolysis in vesicle formation and fission (57). Recently, it was shown that, 
depending on the cellular context, Arf1 is also found at the plasma membrane where it 
may have a role in clathrin and dynamin-independent, Cdc42-mediated pinocytosis. 
However, much additional work is needed to fully understand the role of Arf1 at the 
plasma membrane (71).  
 
Arf6 is localized at the plasma membrane where it has been reported to regulate 
membrane transport (72,73),(74). Arf6 has been shown to be involved in a subset of both 
clathrin-dependent and clathrin-independent endocytosis. Unlike Arf1, Arf6 has not been 
shown to directly recruit coat proteins. However, Arf6 can activate PIP5K as well as 
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Phospholipase D (PLD) (59),(75), and its role in endocytosis has been explained through 
its ability to affect lipid metabolism. For example, PIP2, which is a product of PIP5K 
activation, can recruit clathrin coats to the plasma membrane. Interestingly, PIP5K is not 
only a downstream effector of Arf6, but also uses phosphatidic acid (PA) as a cofactor, 
which is, in turn, a product of PLD, another effector of Arf6 (26). So far, Arf6 has been 
shown to affect GPCR endocytosis through clathrin-dependent endocytosis, and also 
MHC class I proteins, M2-muscaranic acetylcholine receptors, and beta1-integrins 
through clathrin-independent, caveolae-independent endocytosis (26,76).  
 
Arf6 has also been suggested to participate in the recycling of endosomes (77). This 
was first shown in CHO cells where over-expressing either wild-type Arf6, or Arf6 
mutants defective in their ability to hydrolyze GTP (Q71L) or bind GTP (T27N), 
interfered with the recycling of transferrin receptors. Whereas, over-expressing wild-type 
or constitutively-active Arf6 slowed the uptake of the transferrin receptors from the cell 
surface, resulting in their accumulation at the plasma membrane, the over-expression of 
dominant-negative Arf6 resulted in the intracellular distribution of the receptors due to 
the interference with their recycling. While transferrin receptors traffic through a clathrin- 
dependent mechanism, Arf6 was later shown to also affect the recycling of proteins that 
lacked the classical clathrin-dependent sorting signals, such as, MHC class I proteins and 
GPI-anchored proteins (78). This role in recycling by Arf6 has also been shown to be 
dependent on its effects on PLD activity, as Arf6 mutants that are unable to stimulate 
PLD blocked recycling and resulted in accumulation of tubular endosomes (79). 
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Arf6 is also known for its ability to affect actin structures at the cell periphery 
manifested as membrane ruffles, and cell spreading. One of the pathways that has been 
suggested to be responsible for Arf6-mediated membrane remodeling involves the Arf6-
mediated activation of Rac1. As will be discussed below, the Arf6 GEF, ARNO, 
mediated the link between Arf6 activation and Rac activation, by recruiting DOCK180, a 
Rac GEF to the plasma membrane leading to lamellipodia formation (80). However, this 
is not the only pathway that links Arf6 to Rac activation. NM23-H1, a nucleoside 
diphosphate kinase (NDK) that phosphorylates GDP, was found to be an Arf6 effector 
that sequesters Tiam1, a Rac-specific GEF, away from its substrate Rac (81). Thus, 
activated Arf6 led to a decrease in the level of activated Rac in polarized epithelial 
MDCK monolayers. This pathway, where activated Arf6 leads to the de-activation of Rac, 
was suggested to mediate Arf6-dependent disassembly of adherens junctions between 
cells, where actin filaments built up by activated Rac promote the stability of adherens 
junction structures.  
 
In this context, it is worth noting that Arf6 was shown to localize at invadopodia, an 
actin-membrane structure that is thought to be utilized by cancer cells in invasion and 
metastasis  (82),(83). Moreover, Arf6 activity was crucial in mediating matrigel-invasion 
by MDA-MD-231 breast cancer cells. Amongst many potential GEFs for Arf6, GEP100 
specifically mediated this function of Arf6, which, in turn, bound to phosphorylated 
EGFRs directly (84).  
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Cool 
Cool  (for Cloned-out-of-library) is a member of Dbl family of GEFs, activating 
Cdc42 and Rac1 (85). It was co-discovered by the Cerione laboratory (86) and by Manser, 
Lim and colleagues (and named Pix for Pak-interacting exchange factor) (87) as a p21-
activated kinase (Pak)-binding partner from a yeast two-hybrid screen. Cool’s ability to 
regulate Pak activity is dependent on the presence of a short domain called T1, located C-
terminal to the tandem Dbl Homology domain-Pleckstrin Homology, a signature domain 
for Dbl family of GEFs, and upstream of the Cat-binding domain (CBD) located at the C-
terminus. The presence of the T1 domain negatively regulates Pak activity, by inhibitng 
the GEF activity of the Cool proteins. This auto-inhibitory effect can be reversed by the 
phosphorylation of p85 Cool-1 (Cool-1 from now on) at tyrosine 442 located 
immediately downstream to the T1 domain (53). When Cool-1 is phosphorylated at 
Tyr442, its GEF activity is activated.  
 
The phosphorylation of Cool-1 influences another function, namely its ability to act 
as an ‘effector’ for Cdc42. Thus, phosphorylated Cool-1 binds with high affinity to the 
activated, GTP-bound form of Cdc42. Thus Cool-1 not only functions as an upstream 
regulator of its substrate, but also act as a downstream effector (52,53). 
 
Cool has been implicated in many cellular activities, and our laboratory has shown 
that it is a critical mediator of Cdc42-promoted cellular transformation (52). The Cdc42 
(F28L) mutant is capable of the spontaneous exchange of GDP for GTP, while 
maintaining its GTP hydrolytic activity. Its expression in NIH3T3 cells induced cellular 
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transformation (24). The mechanism behind such transformation involves Cool-1. The 
activated, GTP-bound Cdc42(F28L) mutant is able to bind to Cool-1 which, in turn, 
associates with c-Cbl, an E3 ubiquitin ligase that negatively regulates EGF Receptor 
(EGFR)-signaling by initiating its degradation. The Cdc42-Cool-1-Cbl complex 
sequesters Cbl away from the EGFR, prolonging its signaling lifetime.  
 
 
paxillin 
Paxillin is a scaffold protein that is involved in integrin-mediated signaling. It 
contains multiple protein interacting domains; specifically 5 LD domains in the N-
terminal half of the protein, and 4 LIM domains in the C-terminal half (Figure 1.6). These 
domains also contain a number of potential tyrosine and serine/threonine phosphorylation 
sites, and they appear to mediate complex, protein-protein interactions that coordinate 
many different signaling events, making paxillin a central node in integrin-mediated 
signaling. As such, paxillin has been shown to affect cell motility, cell survival, invasion, 
and cell growth (88).  
 
The LIM domains in paxillin are responsible for its localization to focal adhesions 
(FAs) (88). Several of the phosphorylations of serine and threonine residues within these 
domains facilitate the localization (89). PTP-PEST, a phosphatase that has been shown to 
play an important role as a tumor suppressor in triple-negative breast cancers by keeping 
multiple proto-oncogenic tyrosine kinases in check (90) as well as participating in cell 
migration, is recruited to paxillin via an interaction with the LIM domains and functions 
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to de-phosphorylate Tyr118, which, in turn, has been shown to be important in focal 
complex regulation and cell survival (91),(92).   
 
Interestingly, on top of being a localization motif for focal adhesions in paxillin, the 
LIM domains of the paxillin-related homolog Hic-5 or Death-Associated Lim-only 
Protein (DALP), have a role in apoptosis (93). Hic-5 is a close family member of paxillin, 
as is DALP although it only contains the 4 LIM domains. When C2C12, a mouse 
myoblast cell line, was selected to stably express either Hic-5 or DALP and then induced 
to undergo differentiation, these cells underwent rapid apoptosis. The specific study that 
elucidated the role of DALP and Hic-5 as apoptotic factors initially suggested a 
mechanism for how these proteins can contribute to programmed cell death in 
differentiation. It also provided hints as to how these LIM domain-containing proteins 
that are homologous to Hic-5 and paxillin can negatively impact cell growth (94,95). 
 
The LD domains of paxillin, especially the LD4 domain, mediate the ability of 
paxillin to interact with Cat1 (44). This interaction localizes the Cat-Cool-Pak complex to 
paxillin, which in turn, affects cell spreading. Such localization of Cat to paxillin would 
coordinate the localized activation of Rac, and the resulting morphological changes that 
this GTPase triggers (49). The LD2 and LD4 domains have also been shown to interact 
with FAK which regulates ERK activity and survival (88). 
 
Tyrosine phosphorylation of paxillin has been shown to have roles in mediating 
various interactions. Tyr31 and Tyr118, which lie within the N-terminus where all four 
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LD domains are located, are the main phosphorylation targets of the Fak/Src tyrosine 
kinases. These phosphorylation sites have been shown to interact with either the CrkII-
Dock180-ELMO complex which can promote the activation of Rac and Arf6 (96,97), or 
with p120RasGAP which leads to activation of p190RhoGAP and the de-activation of 
Rho activity (98). Both of these interactions have been implicated in regulating Rho 
GTPase-mediated focal adhesion maturation and protrusion. These tyrosine residues have 
also been shown to be important in apoptosis although the mechanism is unclear.  
 
Known cellular functions of Cat  
Cat has been shown to exert diverse cellular functions, mainly through its ability to 
interact with several different proteins. 
 
Cat in focal complex regulation and migration in fibroblasts 
The first indication that Cat can promote cell migration came from an observation 
that over-expressing Cat in NIH3T3 cells or COS-7 cells enhanced the migration rates of 
those cells as read-out by time-lapse microscopy or in Boyden chamber assays (51). It 
was also found that co-expressing Cat and Cool together in cells led to the disassembly of 
focal complexes, and this was accompanied by increased interactions between Cat and 
paxillin. Thus, the interactions between Cat and paxillin were suggested to cause focal 
complex disassembly.  
 
Our laboratory has also recently implicated Cat in the Src-stimulated migration of 
fibroblasts (63). We have shown that the tyrosine phosphorylation/de-phosphorylation 
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cycle of the Cdc42 GEF, Cool-1, regulates the interaction between Cat and paxillin which, 
in turn, drives focal complex assembly and dis-assembly in Src-transformed NIH3T3 
fibroblasts. More specifically, the tyrosine phosphorylation of Cool-1 by Src was 
suggested to weaken the Cool-Cat interaction, while at the same time, enhance the Cat-
paxillin interaction. The enhanced Cat-paxillin interaction was proposed to promote a 
more dynamic focal complex assembly and disassembly cycle, stimulating the migration 
and invasive activity exhibited by these cells.  
 
There have also been reports that describe a role for Cat in cell spreading and, in 
particular, in the formation of lamellipodia. Two mechanisms have been proposed to 
account for this function of Cat. One mechanism has the Pak kinase, which binds to Cat, 
acting as an upstream activator of Rac (99). Thus, when Cat binds to paxillin, Cat is 
localized to the focal complexes and the Rac-mediated protrusion becomes limited. This 
model is supported by the observation in cells where the over-expression of a paxillin 
mutant that lacks the LD4 domain, which mediates the Cat-paxillin interaction, led to Rac 
activation and membrane protrusion (49). 
 
Another mechanism explains the effects of Cat on cell spreading through Cat’s Arf-
GAP activity. That is, the GAP activity of Cat catalyzes GTP hydrolysis by Arf6, which, 
in turn, influences lipid trafficking (100). In this study, it was observed that a Cat mutant 
that lacked the Arf-GAP domain promoted spreading, and this effect was inhibited by a 
dominant-negative form of Arf6, and also by dominant-negative Rac. Dock180, a GEF 
for Rac and a known effector for Arf6, has been suggested to explain the molecular link 
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between Arf6 and Rac (80). That is, activated Arf6 can localize and directly turn-on the 
GEF activity of Dock180 toward Rac.  In fact, the Ginsberg laboratory found that an 
integrin-paxillin complex inhibited stable lamellipodia formation by blocking Rac 
activation and this was dependent on the recruitment of Cat to paxillin (50).  
 
Cat’s role in influencing neuronal cell morphology and in neuronal synaptic activity 
Similar to studies performed in fibroblasts that showed that Cat can impact cell shape 
and migration, the Horwitz laboratory found that Cat-1 can also influence neuronal cell 
morphology (46). In doing so, they identified the Synapse Localization Domain on Cat, 
which lies between the SHD and PBS domains, and it seems to be responsible for 
localizing Cat to synapses in hippocampal neurons. Neurons that over-express SLD 
disrupted the ability of the endogenously expressed Cat to be localized to the synapses, 
resulting in defective spine morphology and dendritic synapse formation in neuronal cells. 
Interestingly, these defects were rescued when an activated form of Rac was ectopically 
expressed in the neurons, suggesting again that Cat can influence cell morphology 
through a Rac-dependent pathway.  
 
Other laboratories have shown that it was the human Scribble (hScrib) protein that is 
responsible for targeting Cat to synapses through its interaction with Cool (101). Scribble 
is a membrane-associated scaffold that was first identified as a tumor suppressor in 
Drosophila (102). It has since been shown to be required for maintaining cell polarity in 
various cell types. Scribble is localized to the plasma membranes because its Leucine 
Rich Repeats (LRR) motif interacts with plasma membranes and its PDZ domain can 
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interact with its binding partners, such as Cool (101). Once at the point of synaptogenesis, 
Ca2+ can activate Cool through a Calmodulin-dependent kinase pathway. Kinases 
involved in Calmodulin-dependent kinase pathways, namely CaMK and CaMKK, were 
shown to phosphorylate Cool-1 at Ser516 site in a Ca2+ dependent manner in 
hippocampal neurons, which in turn led to the activation of Cool’s GEF activity.  
Activating Cool led to the activation of Pak which was necessary for synaptogenesis (47).  
 
Attention deficit hyperactivity disorder (ADHD) has been attributed to defects in Cat-
1 function (103). Through genomic studies, ADHD-associated Single Nucleotide 
Polymorphism (SNP)s were found in the Cat-1 gene in humans. When Cat-1 knock-out 
mice were generated, they displayed behaviors characteristic of ADHD. The Cat-1-/- mice 
showed much higher locomotive activity in open-field tests. In fact, treating these Cat-1-/- 
mice with amphetamine and methylphenidate, psychostimulants commonly used to treat 
ADHD, reversed the hyperactivity in these mice. Cat was shown to be necessary for 
inhibitory transmission at presynapses in hippocampal neruons. The molecular 
mechanism behind the Cat-/--mediated manifestation of hyperactivity was attributed to 
reduced expression levels of Cool-1/Cool-2 in the Cat-/- neurons which resulted in less 
Pak3 activity. However, the exact mechanism behind how the loss of Pak3 activity 
specifically affected inhibitory transmission in the presynapse is not yet understood. 
 
Separately, Cat-1 was shown to bind Huntingtin(htt), a pathogenic protein for 
Huntington’s Disease (HD) and this interaction was correlated with the pathogenicity of 
the disease (67). The C-terminus of Cat-1 was found to interact with htt in a yeast two-
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hybrid screen. When the C-terminal Cat-1 fragment was co-expressed with an N-terminal 
htt fragment containing 68 glutamine residues (HD169Q68) in HEK293 cells, htt 
aggregates were formed to a 3-fold greater extent in the same time period as the amount 
of aggregates formed in HD169Q68-only expressing cells. Accordingly, knocking-out 
endogenous Cat-1 by siRNA dramatically slowed the formation of htt-aggregates. In fact, 
the C-terminus of Cat-1 and the N-terminus of htt interacted in cells, and high amounts of 
the C-terminal, truncated Cat-1 were found in the brains of patients suffering from 
Huntington’s disease. 
 
Cat in polarity 
One common system that is often used to study cell polarization is the wound-healing 
assay. When a scratch, or ‘wound’, is introduced onto a monolayer of cells grown in 
culture with a sharp, narrow-ended object like a pipette tip, the cells that are lining up 
against the wound undergo a drastic, but polarized, change in morphology and 
coordinately start migrating towards the freshly made gap. Cdc42 has been implicated in 
establishing such polarity within migrating cells. The Hall laboratory suggested that this 
function of Cdc42 is achieved through a two-fold mechanism (104). The first is the re-
orientation of the Golgi and centrosome towards the leading edge of the cells (105), and 
the second is the polarized protrusion of the leading edge (104). The directional re-
localization of the Golgi/centrosome has been attributed to the activation of Cdc42 at the 
leading edge which results in the recruitment of the Par6/aPKCz complex and the 
activation of aPKCz along microtubules. The membrane protrusion effect has been 
attributed to the Pak-Cool complex. The localization of the Pak-Cool complex to the 
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leading edge was suggested to restrict the Rac-mediated polarized membrane protrusions 
to the leading edge. This localization of the Cool-Pak complex and the localized 
activation of Cdc42 both involve activation of Cool which, in turn, has been shown to be 
under the regulation of Arf6 activity (106).  Given that Cat has been already been shown 
to mediate the effects of Arf6 on cell protrusion, it is very likely that Cat is involved in 
this role of Cdc42 in cell polarity. In fact, Cat-2 has been shown to be a crucial protein 
for directional migration in wound-healing assays, strengthening the idea that Cat is 
involved in establishing the polarization of membrane protrusion in cells. 
 
GPCR and other receptor internalization  
When Cat was first identified as a GRK-binding partner by the Lefkowitz laboratory, 
the functional consequence of these interactions was shown to be linked to GPCR 
internalization (43). Lefkowitz and colleagues had noticed that the over-expression of Cat 
in cells led to the enhanced phosphorylation of GPCR by GRK as a result of retarded 
internalization of the receptor from the plasma membrane. However, expression of a 
mutant form of Cat that lacked this GAP domain did not lead to the build up of GPCRs 
on the cell surface, suggesting that Cat’s GAP activity is important for mediating this 
outcome. More specifically, it was hypothesized that Cat’s GAP activity toward the Arf6 
GTPase leads to the inactivation of Arf6 which, in turn, blocked the internalization of 
GPCRs. The study was expanded to multiple endocytic pathways utilized by various 
receptors after stimulation. By detecting cell surface receptors by receptor-specific 
antibodies, it was concluded that the endocytic pathways that were affected by the over-
expression of Cat were the same pathways that were under the control of clathrin-
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mediated endocytosis, as well as being under the regulation of dynamin, and beta-arrestin 
(54).  
 
Overview of thesis 
Here I attempt to understand Cat’s potential role in cellular transformation. Despite 
the fact that various binding partners of Cat have been shown to be involved in diverse 
signaling pathways and cellular functions, Cat is mostly known for its ability to influence 
cell morphology and migration. However, I felt that there were good reasons to examine 
the potential involvement of Cat in cellular transformation and growth. One such reason 
is that Cat is a major binding partner for Cool-1 which has already been shown to be a 
critical mediator of Cdc42 F28L-mediated transformation, as well as vSrc-dependent 
transformation. In chapter 2 of this thesis, I show that Cat has an important role in the 
anchorage-independent growth of both Cdc42 F28L-mediated transformed cells, and 
cervical carcinoma cell line, HeLa. Moreover, my results suggest that Cat acts as an 
effector for activated Arf GTPases in promoting transformation. Critical step in the 
effector function of Cat involves its ability to bind to paxillin. In chapter 3, I then provide 
evidence that paxillin is, to our surprise, is a negative regulator of the anchorage-
independent growth. This is suggests that the critical role of Cat in promoting cellular 
transformation is inhibiting the negative impact of paxillin on the aberrant growth of 
cancer cells by binding to paxillin. 
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Chapter 2 
 
The adaptor protein and Arf GTPase-activating protein Cat-1/Git-1 is required for cellular 
transformation 
 
 
Abstract 
Cat-1/Git-1 is a multi-functional protein that acts as a GAP (GTPase-activating protein) for 
Arf GTPases, as well as serves as a scaffold for a number of different signaling proteins.  Cat-1 
is best known for its role in regulating cell shape and promoting cell migration.  However, 
whether Cat-1 might also contribute to cellular transformation is currently unknown.  Here we 
show that ~95% of cervical tumor samples examined over-express Cat-1, suggesting that the up-
regulation of Cat-1 expression is a frequent occurrence in this type of cancer.  We further 
demonstrate that knocking-down Cat-1 from NIH3T3 fibroblasts expressing an activated form of 
Cdc42 (Cdc42 F28L), or from the human cervical carcinoma (HeLa) cell line, inhibits the ability 
of these cells to form colonies in soft agar, an in vitro measure of tumorgenicity.  The 
requirement for Cat-1 when assaying the anchorage-independent growth of transformed 
fibroblasts and HeLa cells is dependent on its ability to bind paxillin, while being negatively 
impacted by its Arf-GAP activity.  Moreover, the co-expression of Cat-1 and an activated form 
of Arf6 in fibroblasts was sufficient to induce their transformation.  These findings highlight 
novel roles for Cat-1 and its interactions with the Arf GTPases and paxillin in oncogenic 
transformation. 
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Introduction 
Cat (for Cool-associated tyrosine phosphorylated), also referred to as Git (for G-protein 
coupled receptor kinase interactor) or PKL (for paxillin kinase linker), is a member of a family 
of multi-functional proteins that are known to regulate the activity of certain members of the Arf 
(for ADP ribosylation factor) family of small GTPases, as well as function as signaling scaffolds 
via its numerous protein binding domains (1-3).  These proteins were discovered more than a 
decade ago through three independent lines of investigation.  In one such study performed by our 
laboratory (1), Cat-1 and Cat-2 were identified as phosphorylated proteins that bound to Cool-1 
(Cloned-out-of-library)-1/beta-Pix (Pak-interacting exchange factor), a guanine nucleotide 
exchange factor (GEF) for the small GTPases Cdc42 and Rac.  This occurred as part of a larger 
effort aimed at identifying proteins that could regulate the activity of the p21-activated kinases 
(Paks), which serve as effectors of the small GTPases Cdc42 and Rac (1).  Although it was 
shown that the Cat proteins do not directly regulate Pak activity (1), it was later demonstrated 
that Cat-1 plays a role in regulating the cellular localization of Pak (4,5) 
 
In a second line of investigation, Git-1 was identified in a yeast two-hybrid screen as a 
binding partner for members of a family of serine/threonine protein kinases, collectively referred 
to as Grks (for G protein-coupled receptor kinases), that phosphorylate activated G-protein 
coupled receptors (GPCRs) (6).  This interaction was suggested to contribute to the 
desensitization and Arf-mediated internalization of GPCRs, through the ability of Git-1 to 
inactivate Arf GTPases by virtue of its Arf-GAP activity (6-8). 
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PKL was identified in yet another screen as a binding partner for paxillin, a scaffold protein 
that plays an important role in regulating the formation of focal adhesions (9).  These dynamic 
cellular structures are composed of various proteins, including integrins, that physically attach 
cells to their extracellular matrix, as well as mediate signaling events that are triggered by 
cellular interactions with the extracellular environment.  With the goal of better understanding 
the proteins that interact with paxillin to regulate focal complex dynamics, PKL was identified as 
a paxillin-binding partner via pull-down assays where the LD4 motif of paxillin was used as bait.  
It was subsequently shown that PKL was responsible for mediating an interaction that occurred 
between paxillin and Pak, an important step in focal complex regulation (4,10).  
 
Since the Cat/Git/PKL proteins (from here on collectively referred to as Cat) are able to 
interact with a variety of signaling proteins, they have the potential to influence several different 
cellular functions.  Indeed, Cat-1 has recently been implicated in stimulating neuronal synaptic 
activity (11), and dendritic spine formation (12,13), as well as in inducing T-cell activation (14).  
Moreover, Cat-1 has been implicated in attention deficit hyperactivity disorder and in 
Huntington’s disease (15,16).   
 
However, most studies to date have linked Cat to changes in cell morphology and migration 
(10, 17-23).  The involvement of Cat in cell migration has stemmed largely from findings 
demonstrating that its over-expression in fibroblasts leads to the loss of focal complexes (18).  
Recently, our laboratory has shown that the tyrosine phosphorylation/de-phosphorylation cycle 
of the Cdc42 GEF, Cool-1, regulates the interaction between Cat-1 and paxillin (20).  This, in 
turn, drives focal complex assembly and dis-assembly in Src-transformed NIH3T3 fibroblasts, 
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thus leading to the enhanced migration and invasive activity exhibited by these cells.  Cat was 
also shown to regulate the spreading of cells by helping recruit Pak or Erk to sites of adhesion 
via its interaction with paxillin (10), Cool-1, and Mek (21,22).  In addition, through its ability to 
function as a GAP and inactivate the small GTPase Arf6, Cat influences lipid trafficking, an 
outcome that also has important consequences in cell spreading (23).   
 
Although Cat-1 has been implicated in the regulation of a number of cellular processes and 
outcomes, an interesting question concerns whether it might contribute to cancer progression and 
the aberrant growth exhibited by transformed cells.  Here we show that this is indeed the case.  
We first demonstrate that knocking-down Cat-1 in NIH3T3 fibroblasts stably expressing an 
oncogenic form of Cdc42, Cdc42 F28L, blocks their ability to exhibit anchorage-independent 
growth.  We then show that Cat-1 is over-expressed in a majority of human cervical carcinoma 
tumors and that knocking-down Cat-1 in a cervical carcinoma cell line (HeLa) blocks the 
transformed phenotypes exhibited by these cells.  We further demonstrate that the ability of Cat-
1 to function as an Arf-GAP, as well as to interact with paxillin, has important consequences for 
cellular transformation.  Moreover, the ectopic co-expression of Cat-1, with an activated form of 
Arf6, is sufficient to induce cellular transformation in NIH3T3 fibroblasts.  Collectively, our 
findings point to an interesting and previously unappreciated role for Cat-1 in transformation and 
cancer progression.  
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Experimental Procedures 
Reagents- The Cat-1, Arf1 and Arf6 antibodies were purchased from Santa Cruz Biotechnology.  
The V5 antibody was from Invitrogen, the HA antibody was obtained from Covance, while the 
actin antibody was from Sigma. 
Plasmids- The human Cat-1 cDNA and the human Arf1 and Arf6 cDNAs were cloned into the 
lentiviral vector pCDH-CMV-MOS-EF1-Puro (System BioSciences).  The QuickChange™ site-
directed mutagenesis kit (Stratagene) was used to generate point mutants of Cat-1 that are 
defective in binding Cool-1 (D294K/E295R) (24), paxillin (K663E/K758E) (25), or are defective 
as an Arf-GAP (R39A) (26).  Likewise, dominant-active forms of Arf1 (Q71L, T161A) (27,28) 
and Arf6 (D125N) (29), as well as dominant-negative Arf6 (T27N) (30), were also generated. 
Lentivirus Generation- The various Cat-1, Arf1, and Arf6 constructs were transfected into 
HEK293T cells using Lipofectamine (Invitrogen).  The mature lentiviruses shed into the 
culturing medium from the transfectants were collected and processed according to the 
manufacturer’s instructions (Systems BioSciences, Mountain View, CA).  
Cell Culture- HeLa cells were grown in RPMI 1640 medium containing 10% fetal bovine serum.  
Parental NIH3T3 mouse fibroblasts or NIH3T3 cells stably expressing a dominant-active form of 
Cdc42 (Cdc42 F28L) or Ras (Ras G12V) were grown in DMEM medium containing 10% calf 
serum. The siRNAs were introduced into cells using Lipofectamine 2000 (Invitrogen), whereas 
the wild-type and mutant constructs of Cat-1, Arf1 and Arf6 were introduced into cells via 
lentiviral infection.  HeLa cells and NIH3T3 cells stably expressing V5-tagged pCDH vector 
alone, or various forms of V5-Cat-1, Arf1, and Arf6 were selected for and maintained by 
supplementing the appropriate growth medium with 0.175 µg/mL puromycin for HeLa cells, and 
2 mg/mL puromycin for NIH3T3 cells stably expressing Cdc42 F28L. 
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Immunoblot Analysis- Cells were lysed with cell lysis buffer (25 mM Tris, 100 mM NaCl, 1% 
Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO4, 1 mM b-glycerol phosphate, and 1 mM 
aprotinin).  The lysates were resolved by SDS/PAGE, and then the proteins were transferred to 
polyvinylidene fluoride membranes.  The membranes were incubated with the indicated primary 
antibodies diluted in 20 mM Tris, 135 mM NaCl, and 0.02% Tween 20.  The primary antibodies 
were detected with horseradish peroxidase-conjugated secondary antibodies, followed by 
exposure to ECL reagent. 
Soft-Agar Assays- HeLa cells, parental NIH3T3 cells, or NIH3T3 cells stably expressing Cdc42 
F28L or Ras G12V transfected with various siRNAs or expression plasmids as indicated, were 
plated at a density of 5 ! 103 cells/mL in medium containing 0.3% agarose onto underlays 
composed of growth medium containing 0.6% agarose in six-well dishes.  The cultures were fed 
once a week, and after 14 days, the colonies were counted. 
Arf GTPase Activity Assays- A glutathione-S-transferase (GST) fusion protein containing the N-
terminal portion of Golgi-associated, gamma adaptin ear containing, Arf binding protein 3 
(GGA3) pre-bound to a glutathione resin was purchased from Pierce.  The activity assays were 
performed according to the manufacturer’s instructions.  
Immunohistochemistry- A human cervical carcinoma tissue array composed of normal cervical 
tissue and cervical tumor samples (U.S. Biomax, Inc., Rockville, MD) was deparaffinized in 
xylene and rehydrated using different concentrations of alcohol.  The antigens were retrieved by 
heating the tissues in a sodium citrate buffer.  After cooling, the tissues were blocked with 3% 
hydrogen peroxide solution, an avidin/biotin blocking solution (Vector Labs), and finally with 
horse serum (Vector Labs).  The slides were then incubated with a 1:50 dilution of the Cat-1 
antibody overnight.  The primary antibody was then detected with the ABC staining kit (Vector 
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Labs) according to the manufacturer’s manual.  The resulting Cat-1 staining was analyzed with 
ImageJ.  
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Results 
To determine whether Cat-1 might contribute to oncogenic transformation, we examined 
whether it was required for the anchorage-independent growth exhibited by NIH3T3 fibroblasts 
stably expressing an oncogenic form of Cdc42, Cdc42 F28L (29).  We began with Cdc42-
transformed cells because we had earlier shown that Cool-1, a known Cat-1-binding partner, was 
essential for their transformation (31,32).  Consistent with previous findings (29,33), NIH3T3 
cells stably expressing the Cdc42 F28L mutant were capable of forming colonies in soft agar 
(Figure 2.1A, control siRNA).  However, when Cat-1 expression was reduced in cells by at least 
70% upon the introduction of either of two different Cat-1-specific siRNAs, there was a 
corresponding reduction in the number of colonies that were formed (Figures 2.1A and 1B). We 
have tried similar knock-down experiments in NIH3T3 cells stably expressing an oncogenic 
form of Ras (Ras G12V), although in these cases it has been difficult to achieve an equivalent 
reduction in Cat-1 expression. Nevertheless, we have found that under conditions where we 
obtained a 40 - 60% knock-down of Cat-1 expression, there was little effect on the ability of  
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Figure 2.1 Cat-1 is necessary for the anchorage-independent growth of NIH3T3 fibroblasts 
expressing an oncogenic form of Cdc42, Cdc42 F28L.  A and B, Two sets of NIH3T3 cells 
stably expressing the Cdc42 F28L mutant were transfected with either a control siRNA or Cat-1 
siRNAs (denoted as Cat-1 siRNA 1 or Cat-1 siRNA 2) as indicated.  A, Soft-agar assays were 
performed on one set of the cells and the resulting colonies that formed were counted.  The 
experiments were performed 3 times, and the results from each experiment were averaged 
together and graphed.  B, The second set of transfected cells was lysed and subjected to Western 
blot analysis with Cat-1 and actin antibodies. The histograms show mean ± standard deviation 
(s.d.). Student’s t-tests between indicated populations are *P<0.01, **P<0.01. C and D, Two sets 
of NIH3T3 cells stably expressing the Ras G12V mutant were transfected with either a control 
siRNA or Cat-1 siRNAs. C, Soft-agar assays were performed on one set of the cells and the 
resulting colonies that formed were counted. The experiments were performed 3 times, and the 
results from each experiment were averaged together and graphed. D, The second set of 
transfected cells was lysed and subjected to Western blot analysis with Cat-1 and actin antibody.  
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these cells to form colonies (Figures 2.1C and 2.1D). This may suggest that Cat-1 is less 
important for the transforming actions of oncogenic Ras. 
 
We next examined Cat-1 expression levels in a variety of different human cancer cell lines.  
Cat-1 is more highly expressed in different cancer cell lines, as well as in NIH3T3 cells 
transformed by the Cdc42 F28L mutant, or by oncogenic v-Src, compared to its expression in 
either normal NIH3T3 cells or the human fibroblast cell line Detroit 551 (Figure 2.2).  Because 
HeLa cells express relatively high levels of Cat-1, we then asked whether it was over-expressed 
in cervical cancers. A human tissue array consisting of 20 normal cervical tissues, together with 
80 cases of primary cervical carcinomas, was subjected to immunohistochemical analysis.  
Figure 2.3A shows that Cat-1 can be detected in the normal cervical tissues, but at relatively low 
levels.  However, the Cat-1 levels detected in nearly all of the cervical tumors were increased 
compared to their normal tissue counterparts.  In fact, over 95% of the tumors were found to 
significantly over-express Cat-1 (Figure 2.3B).  It is also worth noting that a correlation exists 
between tumor grade and the highest levels of Cat-1 expression (Figure 2.3C).  
 
We then asked whether the increased levels of Cat-1 observed in the cervical tumors were 
important for their oncogenic phenotypes by taking advantage of our finding that the human 
cervical carcinoma cell-line, HeLa, expresses relatively high levels of Cat-1 (Figure 2.2).  Either 
control siRNA or two different Cat-1-specific siRNAs were introduced into HeLa cells, and then 
the abilities of the cells to grow under anchorage-independent conditions were compared. Figure 
2.4A shows that the Cat-1 siRNAs were effective at knocking-down Cat-1 in these cells, 
reducing its expression by ~90%.  The ability of the HeLa cells depleted of Cat-1 to form  
 ! #"!
Figure 2.2 Cat-1 is highly expressed in different types of human cancer cells and in 
transformed fibroblasts.  Western blot analysis was performed to detect Cat-1 expression in 
multiple cancer cell lines, mouse fibroblasts that stably express the vector alone or oncogenic 
forms of Src (v-Src) and Cdc42 (Cdc42 F28L) and in a human fibroblast cell line Detroit 551. 
The blot was reprobed with an actin antibody to confirm equal loading. 
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Figure 2.3 Cat-1 expression is frequently enhanced in human cervical cancers.  A, A human 
cervical carcinoma tissue array consisting of 80 tumor samples and 20 normal tissues were 
subjected to immunohistochemical analysis using a Cat-1 antibody.  B, The staining obtained 
with the Cat-1 antibody for each sample in the array was quantified using Image J and then 
plotted based on its relative expression of Cat-1.  Each light colored square represents normal 
cervical tissue sample, while each dark diamond represents an individual cervical cancer case. C, 
The relative Cat-1 expression levels in the normal tissue and tumor samples were plotted based 
on tumor grade (from grade 1 to grade 3, as well as tumor samples whose grade was not 
available (N.D.)). 
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Figure 2.4 Cat-1 is necessary for the anchorage-independent growth of HeLa cervical 
carcinoma cells.  Two sets of HeLa cells were transfected with either a control siRNA or Cat-1 
siRNAs (denoted as Cat-1 siRNA 1 or Cat-1 siRNA 2) as indicated.  A, One set of the cells was 
lysed and then subjected to Western blot analysis with Cat-1 and actin antibodies.  B, Soft-agar 
assays were performed on the second set of cells and the resulting colonies that formed were 
counted.  The experiments were performed 3 times, and the results from each experiment were 
averaged together and graphed. The histograms show mean ± s.d. Student’s t-tests between 
indicated populations are *P<0.01, **P<0.01. 
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colonies in soft agar was significantly impaired compared to the control siRNA-treated cells, 
with at least 3-fold fewer colonies being formed by cells transfected with either of the Cat-1 
siRNAs (Figure 2.4B).  To rule out off-target effects of the Cat-1 siRNAs, a rescue experiment 
was performed where we attempted to restore the ability of HeLa cells transfected with a Cat-1 
siRNA to exhibit anchorage-independent growth by re-introducing a V5-tagged, siRNA-
insensitive form of Cat-1 via lentivirus infection. Figure 2.5A shows that following the 
introduction of this Cat-1 construct into HeLa cells depleted of endogenous Cat-1 (using Cat-1 
siRNA 1), the expression of the V5-tagged Cat-1 was comparable to the endogenous levels of 
Cat-1 detected in the control HeLa cells (Figure 2.5A, compare lanes 1 and 3).  As anticipated, 
restoring Cat-1 expression in these cells was able to completely rescue the growth inhibitory 
effects caused by the siRNA-targeted knock-downs (Figure 2.5B). 
 
Having established that Cat-1 plays an important role in the anchorage-independent growth 
of transformed fibroblasts, as well as HeLa cervical carcinoma cells, we next examined which of 
the functions of Cat (i.e. its Arf-GAP activity, and/or its ability to associate with Cool-1 or 
paxillin) was responsible for mediating these effects.  To address this question, we generated a 
series of V5-tagged Cat-1 mutant constructs that were insensitive to the effects of the Cat-1 
siRNAs (Figure 2.6A).  These various Cat-1 mutants were then introduced into HeLa cells that 
had been transfected with either a control siRNA or a Cat-1-specific siRNA.  Western blot 
analysis was carried-out on the cells to determine the relative expression levels of endogenous 
Cat-1 in the control siRNA- and Cat-1 siRNA-treated cells, versus the levels of each of the 
ectopically expressed mutant forms of Cat-1 introduced into the Cat-1-depleted cells.  Figure 
2.6B shows that each of the siRNA-insensitive forms of Cat-1 expressed reasonably well in   
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Figure 2.5 Re-introducing Cat-1 in Cat-knock-down HeLa cells restores their transforming 
ability.  HeLa cells stably expressing either the vector alone or an siRNA-insensitive form of 
wild-type Cat-1 were generated.  Two sets of the vector alone-expressing cells were transfected 
with either control siRNA or Cat-1 siRNA and serve as the positive and negative controls in 
these experiments.  The HeLa cells expressing the siRNA-insensitive Cat-1 WT were also 
transfected with the Cat-1 siRNA.  A, One set of cells was lysed and subjected to immunoblot 
analysis using Cat-1 and actin antibodies.  B, The second set of cells was subjected to soft-agar 
analysis and the resulting colonies that formed were counted.  The experiments were performed 
3 times, and the results from each experiment were averaged together and graphed. The 
histograms show mean ± s.d. Student’s t-tests between indicated populations are *P<0.01, 
**P<0.01.  
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Figure 2.6 The ability of Cat-1 to interact with paxillin and function as an Arf-GAP is 
important for the anchorage-independent growth of HeLa cells.  A, List of the mutant forms 
of Cat-1 generated and the description of their functional defects.  B and C, HeLa cells 
expressing either the vector alone or the various siRNA-insensitive mutant forms of Cat-1 were 
generated.  Two sets of the vector alone-expressing cells were transfected with control siRNA or 
Cat-1 siRNA, and serve as the positive and negative controls in these experiments.  HeLa cells 
expressing the various mutant forms of siRNA-resistant Cat-1 were also treated with Cat-1 
siRNA.  Later, one set of cells was lysed and subjected to Western blot analysis as indicated (B), 
while the second set of cells was subjected to soft agar analysis (C).  The experiments were 
performed 3 times, and the results from each experiment were averaged together and graphed. 
The histograms show mean ± s.d. Student’s t-tests between indicated populations are *P<0.01, 
**P<0.05, ***P<0.01. 
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HeLa cells where endogenous Cat-1 expression had been knocked-down, with the exception of 
the Cat-1 mutant DKER that is defective in its ability to bind Cool-1 (Figure 2.6B, last lane).  
We tried several different titers of lentivirus as well as varied the amount of virus used to infect 
cells, but were never able to achieve the expression of this Cat-1 mutant.  Consistent with our 
previous results, the introduction of a siRNA-insensitive form of wild-type (WT) Cat-1 into Cat-
1-knock-down HeLa cells rescued the growth-inhibitory effects caused by depleting Cat-1 
expression (Figure 2.6C, compare lanes 1, 2, and 3).  However, cells expressing a mutant form of 
Cat that is defective in its ability to bind to paxillin (i.e. the KK Cat-1 mutant) could not restore 
the anchorage-independent growth of HeLa cells depleted of endogenous Cat-1 (Figure 2.6C).  
Interestingly, the form of Cat-1 defective for its Arf-GAP function (i.e. the RA mutant), not only 
rescued the growth-inhibitory effects of knocking-down Cat-1, but it consistently performed 
better than wild-type Cat-1 (Figure 2.6C, compare lanes 3 and 5). However, the enhanced colony 
formation stimulated by the Arf-GAP-defective form of Cat-1 was again dependent on its ability 
to bind to paxillin, since the Cat-1 double-mutant that is both incapable of functioning as an Arf-
GAP and as a paxillin-binding partner (referred to as the Cat-1 KK-RA mutant) failed to promote 
anchorage-independent growth (Figure 2.6C, compare lanes 5 and 6).  These data suggest that 
the role of Cat-1 in promoting cellular transformation is dependent on its ability to bind to 
paxillin and is consistent with the finding that ectopically expressing Cat-1 in HeLa cells leads to 
increased formation of Cat-1/paxillin complexes, as read-out by the co-immunoprecipitation of 
these proteins (Figure 2.7). Moreover, the enhanced transformation caused by the Arf-GAP-
defective Cat-1 mutant implies that the activation of Arf GTPases could be important for 
malignant transformation.  
 
 ! $$!
 
Figure 2.7 Higher Cat expression leads to enhanced formation of Cat-paxillin complex. 
Immunoprecipitations with a paxillin antibody were performed using extracts of HeLa cells 
ectopically expressing either vector alone, or V5-tagged Cat WT. The whole cells lysates (WCL) 
and the resulting immunocomplexes (IP:pxn) were immunoblotted with a Cat-1 and paxillin 
antibody.  
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We then set out to examine members of the Arf GTPase family that serve as substrates for 
the GAP activity of Cat-1 for their abilities to induce cellular transformation.  We first asked 
whether the levels of activated, GTP-bound Arf1 or Arf6 were affected in HeLa cells under 
conditions where Cat-1 expression was knocked-down by RNAi.  Although the Arf GTPase 
family is made-up of 6 members (Arf1-6), Arf1 and Arf6 have been shown to serve as substrates 
for Cat’s GAP activity in cells (34,35).  Therefore, we compared the relative levels of Arf1 and 
Arf6 activation in cells transfected with either a control siRNA or a Cat-1-specific siRNA, using 
GGA3-GST to pull down activated, GTP-bound Arf1 or Arf6 from cell lysates (36).  Figure 2.8A 
shows that in HeLa cells expressing control siRNA, very little activated Arf1 is detected, 
whereas there is a detectable level of activated Arf6.  However, when Cat-1 expression was 
knocked-down, both the levels of Arf1 and Arf6 activation were increased.  
 
What then are the roles of these Arf GTPases in cellular transformation? To address this 
question, we generated a dominant-active mutant of Arf6, Arf6 D125N, capable of accelerated 
intrinsic nucleotide exchange (i.e. a “fast-cycling” mutant) based on the corresponding mutant 
for Cdc42 that we had previously characterized (29).  In fact, when this Arf6 mutant was 
expressed in HeLa cells, it enhanced their ability to undergo anchorage-independent growth, 
whereas the dominant-negative Arf6 mutant, Arf6 T27N (30), was ineffective (Figure 2.8B).  
Expression of the activated Arf6 (Arf6 D125N) in fibroblasts was not sufficient to induce their 
transformation (Figure 2.8C, lane 2).  The same was true for the activated form of Arf1 (Arf1 
T161A), which was generated based on a previously reported fast-cycling Arf6 mutant (28).  
However, interestingly, when the activated Arf1 and Arf6 mutants were co-expressed in NIH3T3 
cells, colony formation in soft-agar was enhanced (Figure 2.8C, lane 4).   
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Figure 2.8 Cat-1 and Arf GTPases work together to promote cellular transformation.  A, 
HeLa cells stably expressing the vector alone or siRNA-insensitive forms of Cat WT and Cat RA 
were transfected with control siRNA or Cat-1 siRNA as indicated.  Extracts from the cells were 
prepared and subjected to pull-down assays using the GGA3-GST fusion protein as bait.  The 
activated forms of Arf1 and Arf6 were then detected by subjecting the pull-down complexes to 
immunoblot analysis using Arf1 and Arf6 antibodies, respectively.  B, HeLa cells and C, 
NIH3T3 cells stably expressing various combinations of the vector alone, or dominant-active or -
negative forms of Arf1 and Arf6, as indicated, were subjected to soft-agar analysis.  These 
experiments were performed 3 times, and the results from each experiment were averaged 
together and graphed. The histograms show mean ± s.d. Student’s t-tests between indicated 
populations are *P<0.01, **P<0.01 for B, and *P<0.01 for C. D, NIH3T3 cells and E, HeLa cells 
stably expressing various combinations of the vector alone, Cat-1, and a dominant-active form of 
Arf6, as indicated, were subjected to soft-agar analysis. These experiments were performed 3 
times, and the results from each experiment were averaged together and graphed. The histograms 
show mean ±s.d. Student’s t-tests between indicated populations are *P<0.01, **P<0.01 for D, 
and *P<0.01 for E. F, NIH3T3 cells stably expressing various combinations of the vector alone, 
Cat KK-RA, and a dominant-active form of Arf6, as indicated. These experiments were 
performed 3 times, and the results from each experiment were averaged together and graphed. 
The histograms show mean ±s.d. Student’s t-tests between indicated populations are *P<0.01, 
**P<0.01. 
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The rescue experiments from Figure 2.6C suggested not only a novel role for activated Arf 
GTPases in transformation, but they also implied that this function may be dependent upon the 
binding of Cat-1 to paxillin.  We therefore asked if the co-expression of Cat-1 with an Arf 
GTPase could promote cellular transformation.  Figure 2.8D shows that expressing either 
activated Arf6 (D125N) alone in NIH3T3 cells, or Cat-1 alone, did not increase colony formation 
relative to control NIH3T3 cells (i.e., vector alone).  However, co-expressing wild-type Cat-1 
and the activated Arf6 (D125N) mutant gave rise to increased anchorage-independent growth of 
NIH3T3 cells, whereas co-expression of the Arf-GAP-defective Cat-1 mutant, Cat RA, and the 
activated Arf6 D125N mutant, even further enhanced colony formation.  Similar results were 
obtained in HeLa cells (Figure 2.8E). The enhanced transformation that occurs in cells co-
expressing the GAP-defective Cat-1 mutant together with Arf6 D125N was again shown to be 
dependent on the ability of Cat-1 to bind paxillin. Specifically, the co-expression of a mutant 
form of Cat-1 that cannot function as an Arf-GAP and is also defective in binding paxillin (Cat 
KK-RA), together with Arf6 D125N, was unable to induce anchorage-independent growth 
(Figure 2.8F). 
 
Discussion 
Cat-1 is a multi-functional protein that acts as a GAP for the Arf family of small GTPases 
and serves as a scaffold that interacts with various signaling proteins, perhaps most notably 
paxillin and Cool-1 (1-3,6,9).  It has been implicated in a diverse range of cellular activities and 
outcomes, although it has been most often linked to cell morphology and promoting cell 
migration (10-13,17-23).  To the best of our knowledge there has thus far not been any direct 
evidence demonstrating a role for Cat-1 in cell-growth control or in promoting oncogenic 
 ! %J!
transformation.  Here, we establish such a role for Cat-1 by showing that it is essential for 
anchorage-independent growth, an in vitro measure of tumorigenicity, exhibited by NIH3T3 
mouse fibroblasts expressing a dominant-active form of the small GTPase Cdc42, as well as by 
the human cervical carcinoma cell line, HeLa.  Moreover, we show that a vast majority of human 
cervical cancers over-express Cat-1, raising the intriguing possibility that it contributes to their 
progression. 
 
These findings raise some interesting questions regarding how Cat-1 influences the growth of 
transformed cells.  While the underlying mechanisms are likely to be complicated and involve a 
number of different proteins, our findings highlight two functions of Cat-1 that distinctly impact 
cellular transformation.  On the one hand, they point to the ability of Cat-1 to interact with 
paxillin, another protein scaffold that binds various signaling proteins, as being an important step 
for anchorage-independent growth.  This was highlighted by the fact that the mutant form of Cat-
1 that is defective in its ability to bind paxillin fails to rescue the block on transformation caused 
by knocking-down endogenous Cat-1 in the HeLa cervical carcinoma cells, whereas the 
expression of a construct that encodes wild-type Cat-1 and is resistant to RNAi restores 
transformation.  Paxillin has been shown in some cases to be required for the growth of cancer 
cells and transformed fibroblasts (37,38).  These studies together with our own lead to suggestion 
that the formation of a Cat-1-paxillin complex might recruit and/or activate a unique set of 
signaling proteins that stimulate the growth of transformed cells.  We are currently investigating 
whether the binding of Cat-1 to paxillin might potentiate the activation of a specific mitogenic 
signaling pathway(s) that is important for mediating transformation.  
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Additionally, our findings point to a functional interaction between Arf GTPases and Cat-1 
that results in enhanced cellular transformation.  In particular, we found that activated forms of 
Arf GTPases can promote cellular transformation and this effect appears to be dependent on Cat-
1 binding to paxillin, as well as being enhanced in cells expressing a GAP-defective Cat-1 
mutant.  These results are also consistent with our finding that the ectopic expression of a GAP-
defective form of Cat-1 consistently performed better than wild-type Cat-1 in restoring 
anchorage-independent growth to HeLa cells which lacked endogenous Cat-1 because of RNAi-
treatment.  Overall, these findings lead us to suspect that in certain cellular contexts, Cat-1 can 
act as an effector for activated Arf GTPases, perhaps through its ability to bind to paxillin and 
form a signaling scaffold that recruits proteins required for transformation. Indeed, Arf6 has 
already been implicated in anchorage-dependent growth (39) and a role for Arf-GAP as an Arf-
effector has been proposed (40). Moreover, we were able to co-immunoprecipitate an activated 
mutant of Arf6 (Arf6 D125N) with paxillin from cells in which we ectopically expressed this 
Arf6 mutant together with an Arf-GAP-defective mutant of Cat-1 (Figure 2.9). Such an effector 
function of Cat-1 would presumably persist until its Arf-GAP activity converts Arf-GTP back to 
Arf-GDP, leading to a dis-assembly of the signaling scaffold.  
 
Our findings linking Cat-1 to cellular transformation using cell-based assays prompted us to 
consider whether Cat-1 expression was up-regulated in human cancers.  Although we have only 
just begun this phase of our studies by comparing Cat-1 expression levels in human cervical 
cancers to their corresponding normal tissue counterparts, what was especially striking was the 
number of cervical cancers that over-expressed Cat-1.  Nearly 95% of the tumor samples 
examined showed enhanced levels of Cat-1, whereas normal cervical tissue samples showed  
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Figure 2.9 Activated form of Arf6 specifically forms complex with Cat and paxillin. 
Immunoprecipitations with a paxillin antibody were performed using extracts of HeLa cells 
ectopically expressing a paxillin binding-defective and a Arf GAP-defective mutant form of Cat, 
together with either vector alone, V5-tagged Arf6 D125N, or V5-tagged Arf6 T27N. The whole 
cell lysates (WCL) and the resulting immunocomplexes (IP:pxn) were immunoblotted with Arf6 
and Cat-1 antibodies.  
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little, if any, Cat-1 expression.  These findings are in agreement with the role that we have 
identified for Cat-1 in cell culture and thereby raise intriguing possibilities regarding a 
fundamental involvement of this protein in other types of cancers.  
 
 
 
  
 ! %$!
References 
 
1.  Bagrodia, S., Bailey, D., Lenard, Z., Hart, M., Guan, J. L., Premont, R. T., Taylor, S. J., 
and Cerione, R. A. (1999) J. Biol. Chem. 274, 22393–22400 
2.  Hoefen, R. J., and Berk, B. C. (2006) J. Cell Sci. 119, 1469–1475 
3.  Inoue, H., and Randazzo, P. A. (2007) Traffic 8, 1465–1475 
4.  Brown, M. C., West, K. A., and Turner, C. E. (2002) Mol. Biol. Cell 13, 1550–1565 
5.  Zhao, Z. S., Lim, J. P., Ng, Y. W., Lim, L., and Manser, E. (2005) Mol. Cell 20, 237–249 
6.  Premont, R. T., Claing, A., Vitale, N., Freeman, J. L., Pitcher, J. A., Patton, W. A., Moss, 
J., Vaughan, M., and Lefkowitz, R. J. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 14082–
14087 
7.  Claing, A., Perry, S. J., Achiriloaie, M., Walker, J. K., Albanesi, J. P., Lefkowitz, R. J., 
and Premont, R. T. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 1119–1124 
8.  Claing, A., Chen, W., Miller, W. E., Vitale, N., Moss, J., Premont, R. T., and Lefkowitz, 
R. J. (2001) J. Biol. Chem. 276, 42509–42513 
9.  Turner, C. E., Brown, M. C., Perrotta, J. A., Riedy, M. C., Nikolopoulos, S. N., 
McDonald, A. R., Bagrodia, S., Thomas, S., and Leventhal, P. S. (1999) J. Cell Biol. 145, 
851–863 
10.  West, K. A., Zhang, H., Brown, M. C., Nikolopoulos, S. N., Riedy, M. C., Horwitz, A. F., 
and Turner, C. E. (2001) J. Cell Biol. 154, 161–176 
11.  Saneyoshi, T., Wayman, G., Fortin, D., Davare, M., Hoshi, N., Nozaki, N., Natsume, T., 
and Soderling, T. R. (2008) Neuron 57, 94–107 
 ! %%!
12.  Zhang, H., Webb, D. J., Asmussen, H., and Horwitz, A. F. (2003) J. Cell Biol. 161, 131–
142 
13.  Audebert, S., Navarro, C., Nourry, C., Chasserot-Golaz, S., Lecine, P., Bellaiche, Y., 
Dupont, J. L., Premont, R. T., Sempere, C., Strub, J. M., Van Dorsselaer, A., Vitale, N., 
and Borg, J. P. (2004) Curr. Biol. 14, 987–995 
14.  Phee, H., Abraham, R. T., and Weiss, A. (2005) Nat. Immunol. 6, 608–617 
15.  Won, H., Mah, W., Kim, E., Kim, J. W., Hahm, E. K., Kim, M. H., Cho, S., Kim, J., Jang, 
H., Cho, S. C., Kim, B. N., Shin, M. S., Seo, J., Jeong, J., Choi, S. Y., Kim, D., Kang, C., 
and Kim, E. (2011) Nat. Med. 17, 566–572 
16.  Goehler, H., Lalowski, M., Stelzl, U., Waelter, S., Stroedicke, M., Worm, U., Droege, A., 
Lindenberg, K. S., Knoblich, M., Haenig, C., Herbst, M., Suopanki, J., Scherzinger, E., 
Abraham, C., Bauer, B., Hasenbank, R., Fritzsche, A., Ludewig, A. H., Bussow, K., 
Coleman, S. H., Gutekunst, C. A., Landwehrmeyer, B. G., Lehrach, H., and Wanker, E. E. 
(2004) Mol. Cell 15, 853–865 
17.  Frank, S. R., and Hansen, S. H. (2008) Semin. Cell Dev. Biol. 19, 234–244 
18.  Zhao, Z. S., Manser, E., Loo, T. H., and Lim, L. (2000) Mol. Cell. Biol. 20, 6354–6363 
19.  Yu, J. A., Deakin, N. O., and Turner, C. E. (2009) Mol. Biol. Cell 20, 4706–4719 
20.  Feng, Q., Baird, D., Yoo, S., Antonyak, M., and Cerione, R. A. (2010) J. Biol. Chem. 285, 
18806–18816 
21.  Yin, G., Haendeler, J., Yan, C., and Berk, B. C. (2004) Mol. Cell. Biol. 24, 875–885 
22.  Yin, G., Zheng, Q., Yan, C., and Berk, B. C. (2005) J. Biol. Chem. 280, 27705–27712 
23.  Di Cesare, A., Paris, S., Albertinazzi, C., Dariozzi, S., Andersen, J., Mann, M., Longhi, R., 
and de Curtis, I. (2000) Nat. Cell Biol. 2, 521–530 
 ! %&!
24.  Loo, T. H., Ng, Y. W., Lim, L., and Manser, E. (2004) Mol. Cell Biol. 24, 3849–3859 
25.  Schmalzigaug, R., Garron, M. L., Roseman, J. T., Xing, Y., Davidson, C. E., Arold, S. T., 
and Premont, R. T. (2007) Cell. Signal. 19, 1733–1744 
26.  Mandiyan, V., Andreev, J., Schlessinger, J., and Hubbard, S. R. (1999) EMBO J. 18, 
6890–6898 
27.  Tanigawa, G., Orci, L., Amherdt, M., Ravazzola, M., Helms, J. B., and Rothman, J. E. 
(1993) J. Cell Biol. 123, 1365–1371 
28.  Santy, L. C. (2002) J. Biol. Chem. 277, 40185–40188 
29.  Lin, R., Bagrodia, S., Cerione, R., and Manor, D. (1997) Curr. Biol. 7, 794–797 
30.  Peters, P. J., Hsu, V. W., Ooi, C. E., Finazzi, D., Teal, S. B., Oorschot, V., Donaldson, J. 
G., and Klausner, R. D. (1995) J. Cell Biol. 128, 1003–1017 
31.  Wu, W. J., Tu, S., and Cerione, R. A. (2003) Cell 114, 715–725 
32.  Feng, Q., Baird, D., Peng, X., Wang, J., Ly, T., Guan, J. L., and Cerione, R. A. (2006) 
Nat. Cell Biol. 8, 945–956 
33.  Tu, S. S., Wu, W. J., Yang, W., Nolbant, P., Hahn, K., and Cerione, R. A. (2002) 
Biochemistry 41, 12350–12358 
34.  Vitale, N., Patton, W. A., Moss, J., Vaughan, M., Lefkowitz, R. J., and Premont, R. T. 
(2000) J. Biol. Chem. 275, 13901–13906 
35.  Mazaki, Y., Hashimoto, S., Okawa, K., Tsubouchi, A., Nakamura, K., Yagi, R., Yano, H., 
Kondo, A., Iwamatsu, A., Mizoguchi, A., and Sabe, H. (2001) Mol. Biol. Cell 12, 645–662 
36.  Yoon, H. Y., Bonifacino, J. S., and Randazzo, P. A. (2005) Methods Enzymol. 404, 316–
332 
 ! &'!
37.  Sen, A., O'Malley, K., Wang, Z., Raj, G. V., Defranco, D. B., and Hammes, S. R. (2010) 
J. Biol. Chem. 285, 28787–28795 
38.  Wade, R., Brimer, N., Lyons, C., and Vande Pol, S. (2011) J. Biol. Chem. 286, 37932–
37944 
39.  Balasubramanian, N., Scott, D. W., Castle, J. D., Casanova, J. E., and Schwartz, M. A. 
(2007) Nat. Cell Biol. 9, 1381–1391 
40.  East, M. P., and Kahn, R. A. (2011) Semin. Cell Dev. Biol. 22, 3–9 
 
! "#!
Chapter 3 
 
Cat promotes cellular transformation by inhibiting the negative impact of paxillin 
on transformation 
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Introduction 
 Anchorage-independent growth, or the ability of transformed cells to grow without 
being attached to the extracellular matrix, is a unique hallmark of cancer and transformed 
cells. Normal cells have a built-in system that leads to cell death, unless specific 
interactions occur between integrins and the extracellular matrix (ECM) proteins that 
make up the substratum (1). This mode of cell death is called anoikis, the Greek word for 
‘homelessness’, and serves to limit cell growth to conditions only when the appropriate 
cell-ECM contacts are made. Given that the ability of cells to grow and survive without 
being attached to a substratum is thought to be a requirement for cancer cells to 
metastasize, understanding the mechanisms that underlie the ability of cancer cells to 
grow and survive under anchorage-independent conditions is of particular interest in 
cancer biology.  
 
 Cat is an Arf6 GAP and a scaffold protein that we have recently found to be over-
expressed in a majority of human cervical carcinomas (S.Yoo et al., submitted). 
Moreover, knocking down Cat in HeLa cells, a human cervical carcinoma cell line, 
inhibited the ability of these cells to form colonies when grown under anchorage-
! "D!
independent conditions. We then went on to show that Cat’s ability to mediate this effect 
was dependent on its interaction with paxillin. This conclusion was based on the finding 
that a paxillin-binding-defective mutant of Cat, when introduced into cells lacking 
endogenous Cat (due to siRNA knock-down), was unable to restore the ability of these 
cells to form colonies whereas ectopically expressing a wild-type form of Cat was 
effective in restoring colony formation. In order to further understand how Cat and 
paxillin work together to promote tumorigenesis, we set out to better understand how 
paxillin influences cellular transformation. 
 
Paxillin is an adapter protein that has been shown to have a major role in regulating 
focal adhesion dynamics and to participate in promoting integrin-mediated signaling 
events (2) (Figure 3.1). As was one of the first proteins to be identified as a constituent of 
focal complexes (3), paxillin was shown to accumulate at nascent focal complexes in 
migrating cells (4). It was also demonstrated through mutagenesis studies that disrupting 
the phosphorylation of paxillin by tyrosine kinases, such as the focal adhesion kinase 
(Fak), or by blocking paxillin’s ability to interact with proteins like Cat or tubulin, alters 
focal complex dynamics and leads to irregular cell spreading and defects in cell migration 
(5,6). Interestingly, paxillin has also been reported to have a role in promoting the 
aberrant growth of transformed and human cancer cells. For example, paxillin was shown 
to be essential for the Ras-mediated transformation of fibroblasts (7). This role for 
paxillin was suggested to be related to its ability to promote the phosphorylation of Fak in 
suspension, which has previously been shown to have important implications in 
promoting anchorage-independent growth. In another study, it was shown that tyrosine   
! "G!
Figure 3.1.  A schematic showing the various domains of Cat-1, paxillin and Hic-5. 
The diagram shows the domains used by Cat-1 and its binding partners, paxillin and Hic-
5, to interact with each other. Tyrosine residues in paxillin that have previously been 
identified shown to be important for regulating cell migration are denoted. 
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88 in paxillin was de-phosphorylated by protein tyrosine phosphatase receptor T (8). This 
phosphatase is one of the most frequently mutated tyrosine phosphatases in human cancer 
(9). Thus, in colon cancer cells lacking a functional protein tyrosine phosphatase receptor 
T, it was shown that phosphorylation of paxillin on tyrosine 88 was increased and this 
was important for the ability of the human colon cancer cell lines exhibit resistance to 
anoikis. 
 
 Interestingly, the point mutations within Cat that disable its binding to paxillin also 
impair Cat’s ability to bind to another protein, hydrogen peroxide induced clone-5 (Hic-
5), a closely related member of the paxillin family (10,11). Thus, it is possible that the 
interaction of Cat with paxillin, Hic-5, or with both of these proteins, is important for 
Cat’s ability to promote the growth and transformed characteristics of HeLa cells.  
 
 Hic-5 was first identified as a gene whose expression was induced in response to the 
effects of transforming growth factor ! 1 (TGF!1) stimulation on the mouse osteoblastic 
cell line MC3T3 (12). The growth inhibitory effects of TGF!1 were already well 
established by this time. Specifically, Nose and his colleagues had already demonstrated 
that the growth inhibitory effects of TGF!1 were at least partially mediated through the 
up-regulation of hydrogen peroxide (H2O2) production (12,13). Subsequently they 
showed that Hic-5 gene expression is up-regulated in response to H2O2 (hence the name, 
hydrogen peroxide induced clone – 5) and that increases in the expression of Hic-5 were 
responsible for mediating the negative effects of H2O2 on cell proliferation. Subsequently, 
it was realized that Hic-5 shared close structural homology with paxillin through its 
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recurring LD motifs in its N-terminus and multiple LIM-domains at its C-terminus  
(Figure 3.1) (14). Moreover, the localization of Hic-5 in cells was similar to that of 
paxillin, being found at sights of focal adhesions, as well as in the nucleus.  So far, the 
best-known cellular function of Hic-5 is its role in limiting cell growth and in promoting 
cell death (15-17). In the context of anchorage-independent growth, Hic-5 has recently 
been shown to be a major player in mediating the anchorage-dependent cell-cycle arrest 
of the mouse MC3T3 octeoblast cell line through a mechanism that involves its 
translocation from the cytoplasm to the nucleus when cells are detached from their 
substratum (18). Thus, the impact of paxillin and Hic-5 in cancer progression is just 
beginning to be appreiciated. 
 
 Here we have set out to characterize how Cat binding to paxillin and Hic-5 promotes 
the transformed characteristics exhibited by HeLa cervical carcinoma cells. Unexpectedly, 
we show that knocking-down either-paxillin or Hic-5 in HeLa cells enhances the ability 
of these cells to form colonies in soft-agar. In the case of paxillin, we confirmed its role 
in limiting the anchorage-independent growth of HeLa cells by showing that ectopic 
expression of paxillin in HeLa cells causes them to form less colonies compared to 
control cells that over-express the vector alone. Moreover, the growth inhibition caused 
by knocking-down Cat expression in HeLa cells can be overcome by knocking-down 
paxillin, but not Hic-5. Collectively, these results point to a new and unexpected role for 
the focal complex scaffold proteins, paxillin and Hic-5, as negative regulators of cellular 
transformation. Moreover, the data also suggests that Cat’s function in promoting cellular 
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transformation is through its ability to bind paxillin, and thereby regulate their growth-
inhibitory functions.  
 
Experimental Procedures 
Reagents- The Cat-1 antibody was purchased from Santa Cruz Biotechnology, paxillin 
antibody from Millipore. Hic-5, phospho-Erk, phospho-Fak, phospho-S6K, phosphor-Akt, 
phosphor-AMPK, Erk, Fak, S6K, Akt, AMPK antibodies were purchased from Cell 
Signaling.  The V5 antibody was from Invitrogen, the HA antibody was obtained from 
Covance, while the actin antibody was from Sigma. 
Plasmids and siRNA- The chicken paxillin-GFP constructs were from Chris Turner.  The 
QuickChange™ site-directed mutagenesis kit (Stratagene) was used to generate point 
mutants of Cat-1 that are defective in binding paxillin (K663E/K758E) (25), and are 
defective as an Arf-GAP (R39A) (26).  Paxillin-targeting and Hic-5-targeting siRNAs 
were purchased from Invitrogen. 
Cell Culture- HeLa cells were grown in RPMI 1640 medium containing 10% fetal 
bovine serum.  Parental NIH3T3 mouse fibroblasts or NIH3T3 cells stably expressing a 
dominant-active form of Cdc42 (Cdc42 F28L) were grown in DMEM medium 
containing 10% calf serum.  The siRNAs were introduced into cells using Lipofectamine 
2000 (Invitrogen), whereas plasmid transient transfection were introduced using 
Lipofectamine in combination with Plus reagent from Invitrogen. 
Immunoblot Analysis- Cells were lysed with cell lysis buffer (25 mM Tris, 100 mM 
NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO4, 1 mM b-glycerol 
phosphate, and 1 mM aprotinin).  The lysates were resolved by SDS/PAGE, and then the 
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proteins were transferred to polyvinylidene fluoride membranes.  The membranes were 
incubated with the indicated primary antibodies diluted in 20 mM Tris, 135 mM NaCl, 
and 0.02% Tween 20.  The primary antibodies were detected with horseradish 
peroxidase-conjugated secondary antibodies, followed by exposure to ECL reagent. 
Soft-Agar Assays- HeLa cells, parental NIH3T3 cells, or NIH3T3 cells stably expressing 
Cdc42 F28L transfected with various siRNAs or expression plasmids as indicated, were 
plated at a density of 5 " 103 cells/mL in medium containing 0.3% agarose onto 
underlays composed of growth medium containing 0.6% agarose in six-well dishes.  The 
cultures were fed once a week, and after 14 days, the colonies were counted. 
 
Result 
 I have recently shown that Cat, an ArfGAP that contains multiple protein-protein 
interaction domains that mediate its scaffolding function, has an important role in 
promoting the transformed phenotypes of the human cervical carcinoma cell line, HeLa, 
as read-out by their ability to grow and form colonies in soft agar (Yoo et al., submitted). 
Moreover, I found that the ability of Cat to bind to paxillin, another scaffold protein that 
localizes to focal complexes (Figure 3.1) and regulates cell migration, was important for 
Cat’s role in promoting the transformed properties of HeLa cells. Ectopically expressed 
forms of activated Arf GTPase were also shown to contribute to cellular transformation, 
but this was also found to be dependent on Cat’s ability to bind paxillin. Collectively, 
these results suggested a model where Cat, acting as an effector for activated ArfGTPases 
(particularly Arf1 and Arf6), promotes cellular transformation by binding to paxillin.  
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What, then, is the role of paxillin in promoting the anchorage-independent growth of 
HeLa cells? Paxillin has previously been shown to be important for the anchorage-
independent growth of the colon cancer cell lines DLD1 and HCT116, as well as for 
fibroblasts stably expressing the oncogenic H-Ras G12V mutant (7,8). Moreover, paxillin 
was suggested to be critical for the mitogenic signaling initiated by EGF stimulation of 
the human prostate cancer cell lines LnCAP and PC3 (19). These findings initially led us 
to favor the idea that paxillin would have a positive role in promoting the transformed 
phenotypes of HeLa cells. However, when we assayed the ability to exhibit anchorage-
independent growth following the transfection of two different siRNAs targeting paxillin 
(denoted as pxn siRNA#1, and pxn siRNA#2) (Figure 3.2A), we obtained a surprising 
result. Instead of finding that the knock-down of paxillin in these cells inhibited 
anchorage-independent growth, we discovered that reducing paxillin expression levels 
enhanced the ability of HeLa cells to form colonies in soft agar (Figure 3.2A). These 
findings then raised the possibility that Cat, by binding to paxillin, might prevent it from 
repressing cellular transformation.  
 
 The paxillin-binding defective form of Cat (designated ‘KK’ for K663E/K758E 
mutations), not only interferes with Cat’s ability to interact with paxillin, but it also 
inhibits its binding to Hic-5, a close homolog of paxillin (Figure 3.1). Thus, we decided 
to examine whether knocking down Hic-5 in HeLa cells would impact cellular 
transformation. Either control siRNA or an siRNA targeting Hic-5 was introduced into 
HeLa cells, and then the abilities of the transfected cells to grow under anchorage- 
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Figure 3.2 Paxillin and Hic-5 negatively affect the anchorage-independent growth of 
HeLa cervical carcinoma cells.  A. Two sets of HeLa cells were transfected with either 
a control siRNA or siRNA targeting paxillin (denoted as pxn siRNA#1 or pxn siRNA#2). 
One set of the cells was lysed and subjected to western blot analysis using paxillin and 
Cat antibodies. (Top panel), Soft-agar assays were performed on the other set of cells and 
the resulting colonies that formed were counted.  The experiments were performed 3 
times and the results from each experiment were averaged together and graphed. (Bottom 
panel). 
B. Two sets of HeLa cells were transfected with either a control siRNA or an siRNA 
targeting Hic-5 (denoted as Hic-5 siRNA#1). One set of cells was lysed and subjected to 
western blot analysis using paxillin and Cat antibodies. (Top panel), Soft-agar assays 
were performed on the other set of cells and the resulting colonies that formed were 
counted.  The experiments were performed 3 times and the results from each experiment 
were averaged together and graphed. (Bottom panel) 
! #RH!
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independent conditions were compared. Figure 3.2B shows that the Hic-5 siRNA was 
effective at knocking-down Hic-5, reducing its expression by ~60% compared to cells 
transfected with control siRNA. The same cells were then subjected to soft agar assays. 
Interestingly, knocking-down Hic-5 led to enhanced colony formation compared to 
control-siRNA treated cells, suggesting that both paxillin and Hic-5 are capable of 
negatively impacting the anchorage-independent growth of HeLa cervical carcinoma 
cells (Figure 3.2B).  
 
 We then asked if the negative effects that paxillin and Hic-5 have on cell growth also 
occur in NIH3T3 fibroblasts that constitutively express the oncogenic Cdc42 F28L 
mutant (Figure 3.3). We treated these cells with paxillin and Hic-5 siRNAs and then the 
cells were subjected to soft agar assays. Similar to the results we obtained in HeLa cells, 
Figure 3.3 shows that knocking-down either paxillin or Hic-5 in Cdc42 F28L-expressing 
NIH3T3 fibroblasts promoted colony formation in soft agar. Interestingly, simultaneously 
knocking-down both proteins in these cells did not enhance the extent of colony 
formation beyond what was seen when these proteins were individually knocked down, 
suggesting that paxillin and Hic-5 might use a similar mechanism to block cell growth.   
 
 To further confirm that paxillin and Hic-5 negatively impact cellular transformation, 
we next asked whether overexpressing these proteins in HeLa cells would inhibit their 
ability to grow in soft agar. Thus, we transiently over-expressed wild-type and several 
different mutant forms of paxillin in HeLa cells and subjected them to soft agar assays 
(Figure 3.4). One of the two paxillin mutants used lacks the LD4 motif that mediates the  
! #RG!
Figure 3.3 Negative effects of paxillin or Hic-5 on anchorage-independent growth 
are conserved in NIH3T3 cells stably expressing oncogenic form of Cdc42, Cdc42 
F28L cells.  A. NIH3T3 cells stably expressing Cdc42 F28L were transfected with either 
a control siRNA or an siRNA targeting paxillin (denoted as pxn siRNA#1) as indicated. 
Soft-agar assays were performed and the resulting colonies that formed were counted.  
The experiments were performed 3 times and the results from each experiment were 
averaged together and graphed. 
B. NIH3T3 cells stably expressing Cdc42 F28L were transfected with either a control 
siRNA, an siRNA targeting Hic-5 (denoted as Hic-5 siRNA#1), or an siRNA targeting 
paxillin (denoted pxn siRNA#1) as indicated. Soft-agar assays were performed on one set 
of cells and the resulting colonies that formed were counted.  The experiments were 
performed 3 times, and the results from each experiment were averaged together and 
graphed. 
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Figure 3.4 Transiently over-expressing paxillin inhibits the anchorage-independent 
growth of HeLa cells. A, List of the cDNA constructs encoding the various mutant forms 
of either Cat-1 or paxillin used in these studies, and the description of their functional 
defects. B. Two sets HeLa cells were either transiently transfected with vector alone or 
with various mutant forms of either Cat-1 or paxillin as indicated. (Top panel) Soft-agar 
assays were performed on one set of cells and the resulting colonies that formed were 
counted.  The experiments were performed 3 times, and the results from each experiment 
were averaged together and graphed. (Bottom panel), The second set of cells was lysed 
and then subjected to Western blot analysis with anti-V5, anti-GFP, and actin antibodies. 
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paxillin-Cat interaction ("LD4), while the other construct used has the two tyrosine 
residues (tyrosine 31, tyrosine 118) previously shown to be important for migration (2) 
mutated to phenylalanine. HeLa cells were also transfected with the vector only (as a 
positive control), or with a double mutant form of Cat (KK-RA) that is defective in 
binding to paxillin/Hic-5 and in functioning as an ArfGAP (as a negative control). 
Consistent with our earlier findings showing that knocking-down paxillin in HeLa cells 
promoted aberrant cell growth, transient over-expression of wild-type paxillin in HeLa 
cells led to ~50% fewer colonies compared to the vector-alone expressing cells. 
Importantly, the reduction in colony number observed in cells overexpressing paxillin is 
comparable to that in HeLa cells overexpressing the KK-RA mutant of Cat (the form of 
Cat that cannot bind paxillin or function as a GAP). Transient expression of the mutant 
form of paxillin that lacks the LD4 motif ("LD4) and therefore cannot bind to Cat, 
inhibited the anchorage-independent growth of HeLa cells to a similar degree as wild-
type paxillin. However, cells that over-expressed the phosphorylation-defective form of 
paxillin had little effect on the ability of HeLa cells to form colonies in soft agar. These 
findings suggest that it is the phosphorylation of tyrosine 31 and tyrosine 118 in paxillin 
that is critical for the ability of paxillin to negatively influence cellular transformation.  
 
 Given that paxillin inhibits the anchorage-independent growth of HeLa cells as well 
as NIH3T3 cells expressing Cdc42 F28L, it is reasonable to suspect that Cat, by binding 
to paxillin, somehow prevents paxillin from inhibiting the growth of cancer/transformed 
cells. However, can the binding of Cat to paxillin and/or Hic-5 fully explain why 
knocking-down Cat inhibited the aberrant growth of HeLa cells or NIH3T3 cells 
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transformed by Cdc42 F28L? To address this question, we knocked-down both Cat and 
paxillin in HeLa cells and examined whether the cells could still form colonies in soft 
agar. We reasoned that if Cat’s role in promoting cellular transformation is solely due to 
its ability to bind paxillin, then the simultaneous knock-down of paxillin and Cat should 
eliminate the growth inhibitory effects of knocking-down Cat alone. The same reasoning 
would also apply to Hic-5, and additionally, if the binding of Cat to both paxillin and 
Hic-5 were important, then knocking-down both paxillin and Hic-5 should allow cells 
depleted of Cat to regain the ability to form colonies. Figure 3.5 shows the results of 
these experiments when performed using HeLa cells. Whereas the knock-down of Hic-5 
did not rescue the reduction of colony formation that occurred in Cat knock-down cells, 
knocking-down paxillin expression did restore this transformation phenotype. Knocking-
down Hic-5, paxillin, and Cat resulted in nearly the same number of colonies as observed 
when just paxillin and Cat-1 were knocked-down.  
 
 Next, we questioned what signaling events might be responsible for mediating Cat’s 
effects on cell growth (Figure 3.6). Interestingly, when cells transfected with mock 
siRNA or an siRNA targeting Cat were lysed and subjected to Western blot analysis, we 
noticed that the activities of several mitogenic signaling proteins, including Erk, Fak, and 
mTOR (represented by the S6K phosphorylation), were up-regulated in the Cat siRNA 
treated cells compared to the mock-siRNA-treated control cells (Figure 3.6A). The only 
exception to this trend was the PI3K pathway. (Interestingly, knocking-down paxillin 
often had the opposite effect of knocking-down Cat. For example, knocking-down 
paxillin resulted in less phosphorylation of Fak in suspended cells, compared to the levels  
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Figure 3.5 Knocking-down paxillin is able to rescue the ability of HeLa cells 
depleted of Cat to form colonies in soft agar. Two sets of HeLa cells were transfected 
with either control siRNA or with various combinations of siRNAs targeting Cat-1, 
paxillin, Hic-5 as indicated.  
Soft-agar assays were performed on the one set of cells and the resulting colonies that 
formed were counted.  The experiments were performed 3 times, and the results from 
each experiment were averaged together and graphed. (graph), One set of cells was lysed 
and then subjected to Western blot analysis with Cat-1, paxillin, and Hic-5 antibodies 
(bottom panels). 
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Figure 3.6 Cat and paxillin-mediated effects on cell signaling. A. Cultures of HeLa 
cells transfected with either mock, Cat-1, paxillin, Hic-5 siRNAs, and were grown under 
normal (10%FBS, RPMI) conditions for 48 hours and lysed. The whole cell lysates were 
immunoblotted with phospho-Fak, total-Fak, phospho-Erk, total-Erk, phospho-AMPK, 
total-AMPK, phospho-Akt, total-Akt, phospho-S6Kinase, total-S6Kinase antibodies. B. 
Cultures of HeLa cells transfected with either mock siRNA, or siRNAs targeting Cat-1 
and paxillin were grown under normal (10%FBS, RPMI) conditions for 48 hours and 
then lysed. The whole cell lysates were immunoblotted with phospho-Akt, total-Akt, 
phospho-S6Kinase, total-S6Kinase, phospho-Erk, and total-Erk antibodies. 
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of phosphorylated Fak detected in mock-treated cells, whereas knocking-down Cat 
resulted in higher phosphorylation. This was in contrast with the results obtained when 
knocking-down Hic-5.) Also, consistent with the soft-agar result where knocking-down 
paxillin with Cat was enough to reverse the effects of knocking-down Cat alone, treating 
cells with both Cat and paxillin siRNAs reversed the signaling patterns that were 
observed when treating cells with Cat siRNA alone (Figure 3.6B).  
 
Discussion 
 Cat is an ArfGAP that has recently been shown by our laboratory to be important for 
the anchorage-indepenent growth of HeLa cells as well as fibroblasts transformed by an 
oncogenic form of Cdc42 (Cdc42 F28L). We established a potential role for Cat in cancer 
progression by first showing that it was over-expressed in a majority of cervical cancers. 
Using colony formation in soft agar assays as an in-vitro measure of tumorigenicity, we 
then went on to demonstrate that the binding of Cat to paxillin was a key step in the role 
that Cat plays in transformation. Here, I expanded upon the findings by showing that a 
Cat-paxillin interaction seems to inhibit the negative effects that paxillin has on the 
anchorage-independent growth of HeLa cells. In doing so, these findings suggest a novel 
insight as to why Cat binding to paxillin/Hic-5 is important in cellular transformation.  
 
 While I had already shown that the binding of Cat to paxillin was in some way 
important for promoting the anchorage-independent growth of HeLa cells and fibroblasts 
expressing Cdc42-F28L, the underlying mechanism responsible for the actions of Cat 
was unclear. I set out to better understand the mechanism involved by seeing how 
! ##P!
knocking-down paxillin and Hic-5 expression in HeLa cells influenced the ability of 
these cells to form colonies. Surprisingly, neither of these proteins was necessary for the 
transformed characteristics of HeLa cells. In fact, more colonies were formed by HeLa 
cells under conditions where the expression of paxillin or Hic-5 was depleted by siRNAs. 
This result was especially surprising for paxillin because it contradicts previous reports 
that have implicated roles for paxillin in the Ras-induced transformation of fibroblasts. 
However, Hic-5 has been implicated as a crucial mediator of the anchorage-dependent 
growth of normal cells, thus suggesting that it may be possible that knocking-down Hic-5 
expression might actually potentiate the anchorage-independent growth of HeLa cells. In 
this context, I indeed observed that knocking-down Hic-5 in HeLa cells increased colony 
formation in soft agar. I also further confirmed the negative role for paxillin in cellular 
transformation by showing that its over-expression in HeLa cells reduced colony 
numbers. Moreover, I have identified that the phosphorylation of Tyr31 and Tyr118 to be 
important for the paxillin-mediated inhibition of the growth of HeLa cells. It is interesting 
to note that the two tyrosine residues have been previously shown to be necessary for 
binding the Crk adapter proteins, p85 PI3K and p120RasGAP (2). I am now setting out to 
determine whether the ability of paxillin to interact with any of these proteins mediates 
the negative effects that paxillin exerts on cell growth.  
 
 The fact that these focal complex proteins exerted negative effects on cellular 
transformation suggested a mechanistic model by which Cat binding to paxillin and/or 
Hic-5 might be important. Namely, Cat seems to have an antagonistic effect on the 
function of focal complex proteins through its interactions with these proteins. Recently 
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Hic-5 was shown to confer anchorage-dependence by accumulating in the nucleus in 
detached cells, which, in turn, prevented cyclin D from localizing to the nucleus, a critical 
step for cell cycle progression (18). Interestingly, paxillin has also been shown to traffic 
to the nucleus. Thus, it is attractive to consider that paxillin might be playing a similar 
role as Hic-5 in regulating transformation. Cat might, in turn, influence the nuclear 
localization of Hic-5, and potentially paxillin, by binding to these focal complex proteins 
and preventing their nuclear localization, thereby enabling cyclin D to localize to the 
nucleus and allow cell cycle progression to proceed.  
 
 This then raises an important question, namely, is the binding of Cat to paxillin and/or 
Hic-5 the only function of Cat necessary for its effects on cellular transformation? Or are 
there other functions of Cat that are also critical for its role in anchorage-independent 
growth? In the simplest sense, one might predict that if paxillin exerts a negative effect 
on cellular transformation, and that the binding of Cat to paxillin is the only critical 
function of Cat, then knocking-down paxillin together with Cat in HeLa cells should 
rescue the block in colony formation caused by knocking-down Cat alone. A similar 
argument applies for Hic-5. Interestingly, knocking-down just paxillin with Cat was able 
to rescue the block of colony formation by siRNA targeting Cat. This suggested that Cat 
binding to paxillin is sufficient to account for Cat mediated promotion of anchorage-
independent growth. Indeed, we see that it is paxillin, but not Hic-5, that affects cell 
signaling to Cat when knocked-down in cells. In agreement with the soft agar data, 
knocking-down paxillin and Cat together can reverse the effects on signaling that were 
influenced by knocking-down Cat alone. In the near future, we hope to ask how paxillin 
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can negatively impact cell growth and what signals regulate Cat’s inhibition of the 
negative regulatory functions of paxillin. 
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Chapter 4 
 
Conclusion 
 
Understanding the molecular mechanisms that govern the growth and progression of 
human tumors serves as an important basis for the development of novel strategies to 
treat cancers. In this regard, little is known about Cat protein and its role in tumorigenesis. 
Cat is an Arf GAP protein that is also a scaffold that mediates the interactions between 
various proteins. In fact, Cat-1 was originally identified as a binding partner for a number 
of different proteins through pull-down assays. The Cerione laboratory used Cool-1, a 
GEF for Cdc42 and Rac GTPases, to pull-down Cat(1), whereas the Lefkowitz laboratory 
and Grk2(2), while the Turner laboratory used paxillin(3). The ability of Cat to interact 
with any of these proteins, suggests its potential involvement in various cellular functions. 
So far, however, the most-studied function of Cat is its role in cell morphology and focal 
complex regulation.  
 
In my thesis work, I have investigated whether Cat might be involved in promoting 
cellular transformation. There were reasons to suspect such a role for Cat might exist, 
with perhaps the most notable of these having to do with its ability to interact with Cool-1. 
Cool-1 had already been shown to be a critical mediator of Cdc42-F28L-induced cellular 
transformation in fibroblast by not only functioning as a GEF for Cdc42 but also by 
serving as an effector of Cdc42(4). Since Cat-1 can bind to Cool, it made me wonder 
what role Cat might have in promoting cellular transformation.  
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In chapter 2, I address this question and the findings highlight a novel role for Cat in 
promoting aberrant growth phenotypes of transformed cell lines and human cancer cell 
lines. In particular, the results show that Cat is necessary for Cdc42 F28L–mediated 
transformation as read-out by colony formation in soft agar. Also, Cat was frequently 
expressed at high levels in various human cancer cell lines. Since HeLa cervical 
carcinoma cells had one of the highest levels of Cat expression, I subjected a tissue 
micro-array composed of primary cervical carcinoma samples to immunohistochemical 
analysis using a Cat-1 antibody. The results from this experiment showed that over 95% 
of the cervical cancers had higher Cat expression than its normal tissue counterparts. I 
then went on to show that knocking-down Cat expression in HeLa cells blocked the 
anchorage-independent growth of the cells, confirming for the first time a role for Cat in 
promoting aberrant cell growth. These findings raise a number of important questions for 
further study. For example, what other types of cancer require Cat for their progression? 
Since pancreatic cancer cell lines and brain tumor cell lines also express Cat to fairly high 
levels, it would be interesting to probe for Cat expression in pancreatic and brain tumor 
tissue arrays. This will allow us to determine whether Cat over-expression is a feature 
unique to cervical cancers, or whether Cat may be deregulated in several different types 
of human cancers.  
 
We then wanted to learn more about the mechanism underlying the Cat-mediated 
anchorage-independent growth of HeLa cells. The approach that we took to answer this 
question was to introduce siRNA-insensitive forms of Cat that were defective for a 
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specific function(s) into cells in which the endogenous Cat expression was knocked down 
by RNAi and see whether the block in cellular transformation could be restored, or 
‘rescued,’ by a particular mutant form of Cat. This line of study led me to determine that 
the paxillin-binding defective form of Cat could not rescue the Cat knock-down 
phenotype, whereas an Arf GAP-defective Cat, led to an even greater extent of 
anchorage-independent growth compared to HeLa cells expressing the siRNA-insensitive 
wild type Cat construct. This enhanced ability to form colonies in soft agar was also 
dependent on the binding of Cat to paxillin. These results suggested that Cat might be 
working as an effector for Arf GTPases, and that paxillin binding is an important step in 
carrying-out the effector function (Figure 4.1). Such a model would predict that Arf 
GTPases could sufficiently drive cellular transformation, and their transforming ability 
would be dependent on Cat binding to paxillin. Indeed, introduction of activated forms of 
Arf1 and Arf6 GTPases, the two substrates for the Arf GAP activity of Cat, was 
sufficient to induce anchorage-independent growth in NIH3T3 cells. In addition, co-
expressing an activated form of Arf6 with Arf GAP-defective Cat mutant, strongly 
induced colony formation in soft agar, supporting the idea that Arf GTPases can promote 
transformation through Cat. To the best of my knowledge, this is the first demonstration 
that Arf GTPases are sufficient to induce anchorage-independent growth. Moreover, 
these findings also show that Cat is an important mediator of Arf-driven cellular 
transformation.  
 
Since the binding of Cat to paxillin is crucial for Cat’s ability to promote cell growth, 
it was logical to then ask what role paxillin has in cellular transformation. Thus, I  
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Figure 4.1 The molecular mechanism underlying the cellular transformation 
promoted by Cat. Cat promotes transformation presumably by acting as an effector for 
activated Arf GTPases. A critical function of Cat as an effector is the binding of Cat to 
paxillin. Experimental results suggest that the binding of Cat to paxillin is important 
because Cat can inhibit the negative impact that paxillin has on cellular transformation 
through binding to paxillin.
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knocked-down paxillin in HeLa cells and, surprisingly, this led to the enhanced growth of 
colonies in soft agar. Such a result was unexpected, given the previous reports suggesting 
paxillin functions as an important mediator of the transformed phenotypes of several 
colon cancer cell lines and transformed fibroblasts (5,6). Also, ectopically expressing 
paxillin in HeLa cells led to a corresponding decrease in cell growth, suggesting that 
paxillin was limiting cell growth. This finding suggested that the binding of Cat to 
paxillin is important because Cat is preventing paxillin from negatively impacting 
transformation. With this model in mind, I hypothesized that if the binding of Cat to 
paxillin is the only necessary function of Cat to promote cellular transformation, then 
knocking-down paxillin together with Cat in HeLa cells might be sufficient to rescue the 
inhibition on anchorage-independent growth that accompanies knocking-down Cat alone. 
Indeed this was what we observed in HeLa cells, supporting the model where paxillin has 
a negative role in cellular transformation and that the up-regulation of Cat in transformed 
and cancer cell lines further counteract their effects (Figure 4.1).  
 
Cell signaling events influenced by Cat were somewhat counter-intuitive in that the 
activation of many of the mitogenic signaling pathways were up-regulated under 
conditions where Cat expression was inhibited by siRNA. For example, knocking-down 
Cat expression led to increases in phosphorylated EGF receptor, Erk, Fak, and S6K 
activity. This suggested to me a couple of scenarios to explain the apparent discrepancy 
between the signaling events regulated by Cat and the results from soft agar assays where 
Cat was shown to promote oncogenic growth. One possibility is that a mitogenic 
signaling pathway that is critical for HeLa cell growth is down-regulated when Cat 
!! "#(!
expression is knocked-down. In fact, knocking-down Cat leads to a decrease in Akt 
phosphorylation, a key signaling protein that promotes survival, which may account for 
the inhibition of colony formation upon knocking-down Cat expression. Another 
possibility is that it is the up-regulation of the activation of signaling proteins that may be 
responsible for inhibiting cellular transformation when Cat is knocked-down in HeLa 
cells. Such idea is supported by the fact that I was able to partially rescue the block in cell 
growth caused by introducing Cat siRNA into HeLa cells by treatment with rapamycin, 
an inhibitor of mTOR kinase, which blocks the mTOR / S6Kinase pathway (results not 
shown). Excessive mTOR-signaling that accompanies the knock-down of Cat RNAi in 
HeLa cells, may be driving cells to apoptosis. In fact, there have been several studies in 
the literature that showed similar results where treatment of rapamycin led to the 
promotion of cell growth (7-10). One commons feature of these reports was the absence 
of the Lkb signaling pathway in the cell systems that were being used in these studies (7-
10). Namely, in cells where the Lkb kinase, or any of its downstream effectors such as 
the AMP Kinase or Tumor Sclerosis Complex proteins were knocked down, treatment of 
these cells with rapamycin led to enhanced cell growth. Lkb kinase, and its downstream 
effector the AMP Kinase have a major role in detecting low ATP levels in cells. They are 
activated by high levels of AMP or ADP in order to down-regulate mTOR signaling 
when there is little energy available in cells. The Lkb-signaling pathway that down-
regulates cell growth by inhibiting mTOR activity in effect acts to keep cells from 
undergoing energy failure-induced apoptosis. Indeed HeLa cells do not express the Lkb 
kinase supporting this hypothesis. Thus, it will be interesting to see whether Cat is able to 
tune-down excessive signaling by the mTOR pathway.  
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One obvious candidate protein that acts downstream of Cat and can influence 
mitogenic signaling is, again, paxillin. In agreement with the idea that paxillin acts 
downstream of Cat, and the observation that knocking-down Cat leads to activation of 
mitogenic signaling pathways, the over-expression of paxillin alone can promote 
mitogenic signaling in cells (results not shown, (6,11)). Moreover, upon knocking-down 
paxillin expression acts to deactivate the signaling pathways that are activated upon 
knocking-down Cat. Also, in agreement with the idea that paxillin is a negative regulator 
of anchorage-independent growth, over-expressing paxillin in HeLa cells led to decreased 
number of colonies formed in soft agar, despite activating many signaling pathways. 
Importantly, however, over-expressing the paxillin Y-F (Tyr31Phe, Tyr118Phe) mutant, 
did not have any effect on the anchorage-independent growth of HeLa cells. This 
suggested that the two tyrosines on paxillin were mainly responsible for mediating the 
negative effects of paxillin on the anchorage-independent growth of HeLa cells. What 
protein could be mediating such role? One of the best known signaling proteins that 
interacts with the two tyrosines on paxillin is Crk. Crk is an adapter protein with one SH2 
and two SH3 domains, and despite not having a catalytic domain, expression of v-Crk in 
cells induces a large number of tyrosine-phosphorylated signaling proteins and is strongly 
transforming (12). It is tempting to think of a putative model where Cat, by binding to 
paxillin, is preventing paxillin from recruiting Crk to sites where Crk mediates the 
activation of signaling molecules. Perhaps, by binding to paxillin, Cat might be affecting 
paxillin’s tyrosine phosphorylation that is necessary for the recruitment of Crk. Since Crk 
has been shown to have such prominent roles in both receptor tyrosine kinase signaling 
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and also integrin signaling, this model might explain how knocking-down Cat can lead to 
hyper-phosphorylation of many signaling proteins. Crk is also an attractive candidate for 
specifically mediating the negative impact of paxillin on transformation because Crk does 
not bind Hic-5, in accordance with my data that suggests it is paxillin but not Hic-5 that 
has a critical role for Cat-mediated transformation.  
 
What is the general picture that emerges from these findings? It seems that Cat is an 
ArfGAP and also an effector of Arf GTPase that, by coordinating these two roles, 
functions in regulating mitogenic signaling potentially by affecting lipid trafficking 
through binding to paxillin. Important questions that lie ahead are as follows;  
1) What is the effector function of Cat that promotes anchorage independent growth? 
How does Cat cooperate with the activated Arf6 and Arf1 to promote such function?  
2) Does Cat work in general to down-regulate mitogenic signaling, and if so, how does 
Cat do it? Is this at the level of the receptor tyrosine kinase/integrin endocytosis or 
recycling?  
3) Why does knocking-down Cat result in activation of mitogenic signaling when, at the 
same time block anchorage-independent growth? Since this happens in both HeLa cells 
and NIH3T3 cells that express the oncogenic Cdc42 F28L mutant, what is common about 
these cell lines? 
4) How do Cdc42 and Arf6/Arf1 coordinate their actions to carry out cellular functions 
through Cat?  
5) How is Cat’s GAP function activated? Is the binding of Cat to paxillin a necessary step?   
!! "$+!
Cat is a novel protein to be found to have a role in tumorigenesis. This protein is 
especially interesting in that Cat immediately implicates Arf GTPase in cancer as well. A 
good deal has been already studied about how Cdc42/Rac and Arf GTPase affect cell 
morphology and directional migration. Understanding how these GTPases work together 
with Cat to affect aberrant growth will be interesting and could also have broad 
implications.  
  
  
!! "$"!
References 
 
1. Bagrodia, S., Bailey, D., Lenard, Z., Hart, M., Guan, J. L., Premont, R. T., Taylor, 
S. J., and Cerione, R. A. (1999) The Journal of biological chemistry 274, 22393-
22400 
2. Premont, R. T., Claing, A., Vitale, N., Freeman, J. L., Pitcher, J. A., Patton, W. 
A., Moss, J., Vaughan, M., and Lefkowitz, R. J. (1998) Proc Natl Acad Sci U S A 
95, 14082-14087 
3. Turner, C. E., Brown, M. C., Perrotta, J. A., Riedy, M. C., Nikolopoulos, S. N., 
McDonald, A. R., Bagrodia, S., Thomas, S., and Leventhal, P. S. (1999) J Cell 
Biol 145, 851-863 
4. Wu, W. J., Tu, S., and Cerione, R. A. (2003) Cell 114, 715-725 
5. Zhao, Y., Zhang, X., Guda, K., Lawrence, E., Sun, Q., Watanabe, T., Iwakura, Y., 
Asano, M., Wei, L., Yang, Z., Zheng, W., Dawson, D., Willis, J., Markowitz, S. 
D., Satake, M., and Wang, Z. (2010) Proc Natl Acad Sci U S A 107, 2592-2597 
6. Wade, R., Brimer, N., Lyons, C., and Vande Pol, S. (2011) J Biol Chem 286, 
37932-37944 
7. Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, 
R. A., and Cantley, L. C. (2004) Proc Natl Acad Sci U S A 101, 3329-3335 
8. Choo, A. Y., Kim, S. G., Vander Heiden, M. G., Mahoney, S. J., Vu, H., Yoon, S. 
O., Cantley, L. C., and Blenis, J. (2010) Mol Cell 38, 487-499 
9. Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., and Guan, K. L. 
(2004) Genes Dev 18, 1533-1538 
!! "$#!
10. Liu, L., Ulbrich, J., Muller, J., Wustefeld, T., Aeberhard, L., Kress, T. R., 
Muthalagu, N., Rycak, L., Rudalska, R., Moll, R., Kempa, S., Zender, L., Eilers, 
M., and Murphy, D. J. (2012) Nature 483, 608-612 
11. Wade, R., Bohl, J., and Vande Pol, S. (2002) Oncogene 21, 96-107 
12. Feller, S. M. (2001) Oncogene 20, 6348-6371 
 
 
